<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>file_1662650493543</title><meta name="author" content="dsanafawi"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 h1 { color: #17365D; font-family:Cambria, serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 26pt; }
 .s1 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 14pt; }
 .s2 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 11pt; }
 .s3 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11pt; }
 .s4 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10.5pt; }
 .s5 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .p, p { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11pt; margin:0pt; }
 .s6 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 table, tbody {vertical-align: top; overflow: visible; }
</style></head><body><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="15" height="24" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 672pt;text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="71" height="41" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACEAAAAICAYAAAB3R5aRAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAACdElEQVQ4ja2SX0hTcRTHf7+76/4Y3m2phU5a6a5I4gptPhjptCIIair2nEGFGkkQFssCHwxTJobh8kkK5OYwinQVaFD0l3BuEup0xpog9LD0ujt327Xu+fU0kJF78gsHDpzP4XzhezAhBO2EAACvrKwUzfsXKhYXA+Wh0HKJ7eyZfpY1TY+Nu680N12+tpXnnrhuK9PS4g0N9Q56JwxEo1H9xUvNiwX5B2Ys5ZaXNdXVw7mGnO+79fqfz56/uB4KLZuTd+rrbL2/4/EMQgiiAQBjjAnGeNsjhBBECKEoigJCCJJlmaZp+m9iHggsWSRJShei0cxqayWn0+nCqUyHw+G8jo7O8bgUT7/QeN5Odff0clNTntPJ4ObmpsozPX0KIYSCwR+Hurp6XACAfb6Zky0trd+2xlhWVjrhGhnOslZVck3NV2dnZ+eOpYp5aOhxd4Ep31tXa7vvfDg4oBgddX3MyzMEFArFH0EQstRqtYgQQpGIkN12w/7ebC55yzDM6ti4u1WWZZplWc+Ia7S9psY6LIoiE4vFtLFYTCtJ0i6jcd+8cb9xrvPuvacMk7FaWMh6/P6FimAwZC4tPTyZYJVKZdw/7z/K83yOKIpa7HD0PSouPvjBYMhdUmvUG6zJ5E04djoHH3z6/KVepVKJWq02vL6+vgdjTBiG+SUIQtb28SHcfuvmOZOpwDcx+aaR41x3KArD/1irtYpDAIAAALndr5oGnIP9PM9nr62t7fV6fcfb2uzveJ7PlmWZAgAsyzKV3G9TGAAQIQQBAErFAgDCiewiESGzu8fB+XwzJzQazUZRUeHX2lpbX7nlyOtUT7YT+gcdi2A4ItRjlgAAAABJRU5ErkJgggAA"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><h1 style="padding-bottom: 4pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Drug Safety during Pregnancy and Breast Feeding</h1><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:42pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s1" style="padding-left: 48pt;padding-right: 48pt;text-indent: 0pt;text-align: center;">Drug</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s1" style="padding-left: 55pt;text-indent: 0pt;text-align: left;">Pregnancy Recommendation</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s1" style="padding-left: 53pt;text-indent: 0pt;text-align: left;">Breast-Feeding Recommendation</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Abatacept</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Abemaciclib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and data from animal reproduction studies, use during pregnancy may cause fetal harm.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if abemaciclib is present in breast milk. Due to the potential for adverse events in the breastfed infant, the manufacturer does not recommend breastfeeding during</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">therapy and for 3 weeks after the last abemaciclib dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Abiraterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Acarbose</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Acetazolamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Acetylcystiene</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefits &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Acetylsalicylic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible (Low Dose)</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters (Full</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dose)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Aciclovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:66pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Activated Charcoal</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Activated charcoal is not absorbed systemically following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Activated charcoal is not absorbed systemically following oral administration. Breast-feeding is not expected to result in significant exposure to a nursing child.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Adalimumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Adapalene</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:33pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Adefovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Potential Toxicity (Hepatitis B) Contraindicated (HIV)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Adenosine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ado-Trastuzumab</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Emtansine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Aflibercept</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Agomelatine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse effects have not been observed in animal reproduction studies. Due to limited data, the manufacturer recommends avoiding use during pregnancy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if agomelatine is excreted in breast milk. According to the manufacturer, a decision to either discontinue breast-feeding or discontinue therapy should be made, taking into account the benefits of breast-feeding for the child and the</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">benefit of therapy for the mother.</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ajmaline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Other agents are preferred when treating acute arrhythmias in pregnant women; however, ajmaline may be used as an alternative agent. Avoid use in the first trimester</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(Trappe 2010).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if ajmaline is excreted in breast milk.</p></td></tr><tr style="height:121pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Albumin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Animal reproduction studies have not been conducted.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Albumin is an endogenous substance; products are prepared from pooled human plasma. Available data are insufficient to recommend use of albumin to reduce the risk of ovarian hyperstimulation syndrome (Practice Committee 2016). Use for other indications may be considered in pregnant women when contraindications to nonprotein colloids exist (Liumbruno 2009).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Endogenous albumin is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:108pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alectinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on data from animal reproduction studies and its mechanism of action, alectinib may be expected to cause fetal harm if administered during pregnancy. Females of reproductive potential should use effective contraception during therapy and for 1 week after the final dose. Males with female partners of reproductive potential should use effective contraception during therapy and for 3 months</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">after the last dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if alectinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for 1 week after the final dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alendronate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alfacalcidol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Alfacalcidol may be present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alfuzosin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if alfuzosin is excreted in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alirocumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Allopurinol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:90pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alpelisib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to alpelisib may cause fetal harm.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">It is not known if alpelisib is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 24pt;text-indent: 0pt;text-align: justify;">Due to the potential for adverse events in a breastfed infant, breastfeeding is not recommended during therapy and for 1 week after the last alpelisib dose.</p><p class="s3" style="padding-left: 5pt;padding-right: 52pt;text-indent: 0pt;text-align: justify;">Also refer to the Fulvestrant monograph for additional information.</p></td></tr><tr style="height:90pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alpha Lipoic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events were not reported in animal reproduction studies. Information related to the use of thioctic acid in pregnancy is limited. According to the manufacturer, the decision to continue therapy during pregnancy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if thioctic acid is present in breast milk. Breastfeeding is not recommended.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alprazolam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alprostadil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Alprostadil is not indicated for use in women. The manufacturer of Muse recommends a condom barrier when being used during sexual intercourse with a pregnant</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">woman.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alprostadil is not indicated for use in women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Alteplase</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amantadine</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydrochloride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:108pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ambroxol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies. Ambroxol crosses the placenta. Ambroxol administration to women in premature labor has been evaluated for the prevention of neonatal respiratory distress syndrome (Zhang 2013). Avoid use in the first trimester; recommendations vary with respect to use in later pregnancy, based on limited controlled data (consult</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">specific product labeling).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Breast-Feeding Considerations</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Ambroxol is present in breast milk. Breastfeeding is not recommended.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amethocaine Drops,</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amikacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amiloride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:165pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amino Acids</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Following administration, an increase of some amino acids is observed in the fetus (Ronzoni 1999; Ronzoni 2002).</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Severe malnutrition during pregnancy is associated with congenital malformation, preterm delivery, low birth weight/intrauterine growth restriction, and perinatal mortality. Parenteral nutrition should be considered when nutritional requirements cannot be met via oral or enteral intake during pregnancy. In women with nausea and vomiting of pregnancy, total parenteral nutrition should be used as a last option for any woman who cannot maintain her weight because of vomiting; enteral nutrition is preferred (ACOG 189 2018).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Endogenous amino acids are present in breast milk (IOM 1991). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Aminophylline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amiodarone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amitriptyline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amlodipine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amoxicillin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Amphotericin B</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ampicillin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:94pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Anastrazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 17pt;text-indent: 0pt;text-align: justify;">Based on the mechanism of action and information from animal reproduction studies, anastrozole may cause fetal harm if exposure occurs during pregnancy.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Evaluate pregnancy status prior to therapy. Females of reproductive potential should use effective contraception during therapy and for at least 3 weeks after the last</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">anastrozole dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 38pt;text-indent: 0pt;text-align: left;">It is not known if anastrozole is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for 2 weeks after the last anastrozole dose.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Anidulafungin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:308pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Anti - D (RH0)</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Immunoglobulin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Available evidence suggests that Rho(D) immune globulin administration during pregnancy does not harm the fetus or affect future pregnancies.</p><p class="s4" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Rho(D) immune globulin (RhIG or anti-D immune globulin) is administered to pregnant females to prevent alloimmunization of RhD-negative mothers who may potentially have a fetus who is RhD-positive. Administration of the immune globulin prevents the mother from developing antibodies to the D antigen and the development of hemolytic anemia in the newborn. Current guidelines recommend administration of RhIG to all pregnant females who are RhD-negative and who are not already RhD alloimmunized at 28 weeks&#39; gestation (unless paternity is certain and the father is documented to be RhD-negative); within 72 hours of delivery of an RhD-positive infant; after obstetric complications (such as a pregnancy loss, abdominal trauma, antenatal hemorrhage); or after invasive diagnostic procedures (such as amniocentesis or chorionic villus sampling). If RhIG not given within 72 hours of delivery or another sensitizing event, there may still be benefit if administered within 28 days (ACOG 181 2017; Fung 2018).</p><p class="s4" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">In pregnant women who require treatment for ITP, other agents are preferred. RhIG for this indication in pregnancy is</p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">limited to case reports and small studies (Neunert 2011).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: justify;">The purified immune globulin in these products is obtained from human donors; the Rho(D) antibodies are endogenous to human plasma.</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Adverse events in the breastfeeding infant have not been observed when administered to women for the suppression of RhD isoimmunization. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Antihemophilic Factor</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(Human)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—No Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:117pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">Antithymocyte Globulin (Rabbit)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Antithymocyte globulin (rabbit) is a purified immunoglobulin G. Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis.Information related to the use of antithymocyte globulin (rabbit) during pregnancy is limited</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 8pt;padding-right: 18pt;text-indent: 0pt;text-align: justify;">It is not known if antithymocyte globulin (rabbit) is present in breast milk.</p><p class="s3" style="padding-top: 6pt;padding-left: 8pt;padding-right: 9pt;text-indent: 0pt;text-align: justify;">Because other immunoglobulins are present in breast milk, the manufacturer recommends that breastfeeding be discontinued during antithymocyte globulin (rabbit) therapy.</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Apalutamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to apalutamide</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">may cause fetal harm and potential fetal loss.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if apalutamide is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Apixaban</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Apomorphine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Aprepitant</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Aripiprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:150pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Artesunate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in some animal reproduction studies. Studies in pregnant women have not revealed an increased risk of congenital abnormalities in newborns (Kovacs 2015, McGready 1998, McGready 2008). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because P. falciparum malaria can cause maternal death, congenital malaria, and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Artesunate is recommended for the treatment of severe malaria in pregnant women (Kovacs 2015).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Low concentrations of the active metabolite of artesunate (dihydroartemisinin) can be detected in breast milk. Adverse events in the nursing infant would not be expected.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ascorbic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atenolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:91pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atezolizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action, atezolizumab is expected to cause fetal harm if used during pregnancy. Verify pregnancy status prior to treatment initiation in females of reproductive potential. Females of reproductive potential should use effective contraception during therapy and for at least 5 months after the last atezolizumab dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if atezolizumab is present in breast milk; however, IgG immunoglobulins are found in milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy or for at least 5 months after the last atezolizumab dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atomoxetine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data, Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data, Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atorvastatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated 1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:181pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atosiban</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Atosiban crosses the placenta with a fetal/maternal concentration ratio of 0.12 for healthy women at term. No direct physiologic effects (heart rate, blood flow) or abnormal fetal movement were observed during in utero exposure in a controlled study of 17 women (de Heus 2009). In general, data on long-term outcomes from in utero exposure to tocolytics is limited (NICE 2015).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Atosiban is only indicated for use in women between completed weeks 24 to 33 of gestation. Tocolytic therapy, including atosiban, has not been clearly shown to improve perinatal/neonatal morbidity or mortality (Haas 2012; NICE 2015). Atosiban may be considered for tocolysis if first-line therapy is contraindicated (NICE 2015).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atosiban (and main metabolite) are present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Atropine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Axitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Azacitidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Azathioprine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Azelastine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Azithromycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:90pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Bacillus Calmette and Guerin 81 mg Injection INTRAVESICAL ONLY</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. BCG (intravesical) is not recommended for use in pregnant women. Women of childbearing potential should be advised to avoid pregnancy while on BCG (intravesical) therapy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">It is not known if BCG (intravesical) is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breast-feeding or avoid use of BCG (intravesical), taking into account the importance of BCG (intravesical) to the mother.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bacillus Calmette and</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Guerin Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Baclofen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:61pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Baricitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 9pt;text-indent: 0pt;text-align: justify;">It is not known if baricitinib is present in breast milk. Due to the risk of adverse events in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Barium Sulfate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Barium is not systemically absorbed; use is not expected to result in exposure to the fetus. Information related to barium exposure in pregnancy is limited (Han 2010; Han</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">2011).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Barium is not systemically absorbed; use is not expected to result in exposure to a breastfeeding infant.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Belimumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bemiparin Sodium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies. Information related to the use of bemiparin is limited (Alalaf 2012; Alalaf 2015).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if bemiparin is excreted into breast milk; breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bendamustine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Benzocaine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:78pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Betahistine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Adverse events were observed in some animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">It is not known if betahistine is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Betamethasone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bevacizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Limited Human Data—Probably Compatible (Intravitreal) Potential Toxicity (Intravenous)</p></td></tr><tr style="height:121pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bicalutamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Bicalutamide is contraindicated for use in women, including pregnant women.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and findings in animal reproduction studies, bicalutamide may cause morphological changes in spermatozoa, inhibit spermatogenesis, and impair male fertility. Males with female partners of reproductive potential should use effective contraception during therapy and for 130 days</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">after the last bicalutamide dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if bicalutamide is present in breast milk. Use is contraindicated in women.</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bilastine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Information related to the use of bilastine in pregnancy is limited.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Antihistamines may be used for the treatment of rhinitis and urticaria in pregnant women. Although second generation antihistamines are preferred, agents other than bilastine are currently recommended (Murase 2014; Wallace 2008; Zuberbier 2014).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if bilastine is excreted in breastmilk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bimatoprost Drops,</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bisacodyl</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bisoprolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bivaluridin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bleomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bosentan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Botulinum Toxin Type A</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Brentuximab Vedotin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:121pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bromazepam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies. Benzodiazepines have the potential to cause harm to the fetus. An increased risk of fetal malformations may be associated with first trimester exposure (malformations of the heart, cleft lip/palate). Maternal use later in pregnancy may be associated with adverse events in the fetus (irregular heart beat) and neonate (hypothermia, hypotonia, respiratory depression, poor feeding, and</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">withdrawal).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Bromazepam and metabolites are expected to be found in breast milk, therefore, use while breast-feeding is not recommended by the manufacturer. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines (Iqbal, 2002).</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Budesonide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Compatible (Inhaled/Nasal) No Human Data—Animal Data Suggest Risk (Oral)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bumetanide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:136pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Bupivacaine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies. Bupivacaine crosses the placenta. Bupivacaine is approved for use at term in obstetrical anesthesia or analgesia. [US Boxed Warning]: The 0.75% is not recommended for obstetrical anesthesia. Bupivacaine 0.75% solutions have been associated with cardiac arrest following epidural anesthesia in obstetrical patients and use of this concentration is not recommended for this purpose. Use in obstetrical paracervical block anesthesia is</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">contraindicated.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Bupivacaine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Buprenorphine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">bupropion</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cabazitaxel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cabergoline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cabozantinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Caffeine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcipotriol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcitonin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcium Carbonate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:75pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcium Chloride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcium Folinate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:76pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcium Gluconate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Calcium is present in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011).</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Calcium Hydroxylapatite</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Reproduction studies have not been conducted. Pregnant women and women of reproductive potential who were not using effective contraception were excluded from</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">clinical trials</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if calcium hydroxylapatite is excreted in breast milk. Lactating women were excluded from clinical trials.</p></td></tr><tr style="height:108pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 27pt;text-indent: 0pt;text-align: left;">Calcium Polystyrene Sulphonate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Does not undergo gastrointestinal (GI) absorption. There are no adequate and well-controlled studies in pregnant women. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">2003).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Does not undergo GI absorption</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Candesartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Capecitabine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Captopril</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbachol, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbamazepine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbetocin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use in pregnancy prior to delivery is contraindicated. Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;line-height: 14pt;text-align: left;">oxytocin overdosage (eg, hyperstimulation of uterus, uterine rupture).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbetocin is present in breast milk.</p></td></tr><tr style="height:20pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbidopa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse" cellspacing="0"><tr style="height:262pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Carbimazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carbimazole crosses the placenta.</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Birth defects have been observed in neonates exposed to maternal carbimazole during pregnancy and include cardiovascular, gastrointestinal, renal, and skull defects. Uncontrolled maternal hyperthyroidism may also result in adverse neonatal and maternal outcomes. Antithyroid drugs are the treatment of choice for the control of hyperthyroidism during pregnancy, although recommendations for specific agents vary by guideline (Alexander 2017; De Groot 2012). To prevent adverse pregnancy outcomes, maternal TT4/FT4 should be at or just above the pregnancy specific upper limit of normal (Alexander 2017). When treatment with carbimazole is needed in pregnant women, therapy should be at the lowest effective dose, and may be discontinued 3 to 4 weeks prior to delivery to reduce the potential risk of neonatal complications. Some manufacturers recommend not exceeding 15 mg/day in the third trimester (Camen product labeling 2015).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Carbimazole is present in breast milk. Breastfeeding is not recommended by the manufacturer and contraindicated in some countries (consult product labeling).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carboplatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Carboprost</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Contraindicated (Unless for Termination/Evacuation of Pregnancy)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Carvedilol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Caspofungin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefazolin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefdinir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefepime</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Cefiderocol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;line-height: 14pt;text-align: left;">No Human Data, but in general, an increase in most types of birth defects or adverse maternal or fetal outcomes was not found following exposure to cephalosporins.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if cefiderocol is present in breast milk</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefixime</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefprozil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ceftazidime</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ceftriaxone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cefuroxime</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Celecoxib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cephalexin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ceritinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Certolizumab Pegol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cetirizine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cetrorelix</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use is contraindicated in females who are pregnant. Resorption resulting in fetal loss would be expected if used in a pregnant woman. Evaluate pregnancy status before</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">beginning treatment.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if cetrorelix is excreted in breast milk. Use while breastfeeding is contraindicated.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cetrolizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cetuximab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Chlorhexidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Chloroquine Phosphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Chlorpheniramine</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Maleate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cholecalciferol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cholestyramine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:151pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Choriogonadotropin Alfa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Chorionic gonadotropin (recombinant) is approved to be used as part of an assisted reproductive technology (ART) program; use is contraindicated in an established pregnancy.</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Ectopic pregnancy, premature labor, postpartum fever, and spontaneous abortion have been reported in clinical trials. Congenital abnormalities have also been observed; however, the incidence is similar during natural conception. For use only by physicians who are thoroughly familiar with infertility problems and their management. Multiple births may result from use of this medication.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if chorionic gonadotropin (recombinant) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering chorionic gonadotropin (recombinant) to nursing women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cinacalcet</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAUYAAAAICAYAAACF8lZYAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAASe0lEQVRoge1Zd1RU17r/zpkZZigDQxdRFCkiaCyJsUQlKlyuBjUKJJrYNQoqilhyNbGAAgIaIbGhIBpAURGxICJYkKKI9N6kOUMvA0xhZs7Z7w89yXEcjMl9efet9d5vrbPWnO+3v+/77b73GUAIgaqHJEnw8w+MdXFd2uXqtrSzvb1jKEII7ty5656Xlz+XKldVVT0pKvrSAZIk4ebN21vy8gt+45pbWkaeP3/BnyRJSE5OWf047clXFMcXCEZFRl70I0kS6LFu3Li5jW77qw9BEHhFReVkeiySJH97qHzx8Qle/26uN/mwlNQHK9LS0t3q6xts/zti/h1PfHyCV8yl2B/b29tNpVIp58SJUycGa2+BQDDq4cPHy1JSH6wgCAL7u7XdSby7MSoq5kBra9twmUym9ssvp04Opq2lpWXEg4ePvrmfkrqSIAhceezKZDK1svKKKdfjE7wCg45G+fr6XZfL5UyqTErqgxWlpWXTPlRbb2+v7uHDAdcePUpbSmlqaGi0iYqOOaCqvEQi0djovrnIxXVp15q131XTcycmJm2Ii4vfMdg4irt+w/vFi9x/KNeprLx8ikgk4tLt7e3tpvv3+9ySSCSaquKRJAlNTU3Wra2tZlKplPN39V1W1tOFLq5Lu11cl3ZFRf3eJv39/dq+h/yut7W1DaNsPT1C/YjzFwKodiRJEk6fOXuc0ieTyVlbt3lnu7gu7frm21WvJBKJxv/E3KA/OAwCkiQZNTU1H8+f/8+ws2GnbA0M9AUAAPn5BQ7hEZHBCCEMIQQXL0b5ZWY+XQwAWEFh4ZwzZ86GkiSJI4QgOvrSwZwXufMBALKyni4+f/7iEYVCwUQIQXTUJZ/nOa+5N/nw4yE/n7/4a/Thjo6OYYPp+lCIxWJudvbzBX19fXqULSHhlpePr19CQEDQFZlMxk5MTNrEFwislH3fdBb2Z3NytbS6uVytrq7u7iH/rv6/CxKpVCs5OWUdhuHk02fZi9IzstxIEqkcBxwOpx9n4AomgyGXSqVaf7c2mUzOSb6fsg4BwnJe5M578PDRSoVCwVJVls3miBk4Q8FisQYkEgmXsiOE4Oq169+vXbex5t695O94Ojrti79cFOLt7bWGyWQqqHJhYeEhAwMDmh+qDcMwsqCwcE5Nbe1EDHs9NK5cjdtTV9cwTlV5obDXsLGxyXbvnu+/Cjl+dCo9d0dH57BLl6/sIwiCSfcRiUTa2713PVXncPrHj//oEZ17kp7x1eHDAfE+vn4JCKHf7AwGU15YVDwnK+vpl6p0IISw9PRMt5TUhyvT0tKXfWh9/yyqqmom83i81rAzJ+zc3FwC6fpqamon3bx1x5Oy1dXVjY+Li99VWVX9KQBAbm6e061bd7a2traZAwCIRP28+vr6cV5enutPngidwOFwxH+X7sGANzQ02jU3N4+iNzYAAIPBIKZOnXKzorxiqq6ubitl9/DY6MnnC6wfPnz8bXFxiX1efoHjtq2bN2AYhrZs3uTR3tZulpiY5N7Y2GT7+PGTbzZv8tiEYRh4em5yFwqFRrdvJ26pr68f9yQ94+stm903UYMsLi5+p1Qq1Zw+beqN06fP/qKshwK1olO/B4O6unq/paVFXlVV9acIIQwAwNl5/sntXp7r169fu1NNTW1gMN/k5JR17h5bSp49e+5MEASDzpEkiQkEzRZpaelfvdWQOI4+/njSvdTUh6v0dHVblDXT47S1tw+ndniKHxgYUFdejBFC8CQ9wzUgICh2z959Kb6H/ON7enoMlfVSGxHlQ5IkriovAICVpUWuvr6eQF9fr9nI0LBJIpFoMRg4qaodeDxemy5Pt7W0rHyGhoZG32DtRYHa9AYDQRCMqKiYg/sP+N7Zs3dfSlR0zEE6bzHKvIDH47UaGxk1GhsZNQwMDKgzGAyFqlg6OtrtBoYGr4qKimdramoK6dyzZ9kLBwakGpMmTbw/e7b9JSsry1xNTY3eP9IP8Lp/ZTIZWyaTcahxAwCgpaUlNDU1rTY3H1lM2YYPM61kMZlyVXGMjY0abMeMyaqprZ2kra3dSecWL174k1gs1hYIBBZ0e15egWNDQ+PY/PwCB7lcrkbZZTK52pUr1/acOXPSbqjJkNrSsvLPKE5Xl9c247Pp1wsLi2er0oHjOJo1a+ZVHR2djpmzZlxR7p+y8vJpCoWCqez3+uQmY6viVOHzz2de5vP51ggBxmazpZSdw2FL5s+fF1ZTU/sxZRs//qOHn9vPig0PP3+UJEk88sKvAYsWLQg1MxteDgDA4/HaJ0wYn1pdXfMJj6fToSrf+9YH5TH/IXh9ypdqVlZWTZZIJJr4yZOnTwQcCb5CTSY6rK0sXwzIZBp0m76+XvPaNau+j7zwa8CFi1F+CxZ8cdLGZvRzAAA9Pd3Wje7fbbv4a5RfeMT5ow5z51y0tbXJeu2n37xxw/rtMZdiD4RHRAY7Os6NHDPG5ikAQHNzi3l0zGWf1atW7l29esXe5zkv5j99lr1IVQXi4xN2xF65thcAoKSkdKaqMmKxmLtn777U/PxCBz//I9fq6urHAgCwWCx5V1e3yXbvnc+6u3uMVPk+fPT4m7t377mLxRLto8d+ivLesTurvf33E2xERGTwmbBzodOnT034PZ9E68aNm1579+5PLSktnZn9PMeZHjMxMcnd3z/wKvV+PS5+1/IVa/iZmU+XkCSJnQk7F7p23YaaU6fCTtI7vEcoNEpIuLU9PSPT1dx8ZNHz5zlfSKXvnnICA49eqq19OREAIDs7Z0F4RGQQQgjup6Su2bfPJ4le1tDQsLGzo9P0zStC6N3TIkIIq66u/tg/IPDqpcux+1NSHqyWy+UsGg9lZeXT6WNGKpWqe2zyLCooLJwLACCTydh9/f08etyi4hL7xLv3PIqLS+zNhg8vKykpe6v/DA0NGzs7O03ftAFCCDEA4J3NoqamdsKRwODY6OgYn9TUh6sHZDIOxWMYBsFBAZ8HBQXYR0REBh8P+TlcJpOxleuoCn19/bxDh/xvuHtsKVm5al19Tk7uPDo/dKhJdUtLqzn1zmQy5T1C4TsbFYXRNtbZAoHAUtnO5XJ7DAwMmkQi8VvtM2PG9OsrVy7/kSAJFs5gEJT97t0kdycnx/NcLa0ec3PzIgFfYE33s7K2etEvEumq0oAQghMnT59qFjRbbN68tTAxMcmDzsfHJ+wICf0lXHlTzszMWrJli1f+mrUbaiMiIgP5fL6VVCrVIAiCoWpRMjMzK9PT1W3u7u4yUeZGjjArEYvEOtQ7hmHg4bHBs76+YWxg0NGYnp4e41Url/9I97EZPTq7WdBsoRwLAEAqlWq8fFk3QRWXkvJgzQ8/7L+vqh0oDAwMcPLy8h0BXm/WjY1NNoGBRy+HhZ0LuX79xs7Va76rYwYEHHYgCILFYDDeOTWw2RzJGJvXCxsdzs7zT6c9SV/a2tpqHuB/yJHOOTrMvZCZkeVaXlE5LTLynDl1IgQAcHJyDM/IzHKprq755Ie9/3KjuHPh549ZWIzKmzFjehyO4+iLL+adOXcu4qepUz69heP4W70wb57TWZlMzgEAiIqKObRtm+d6ptKufSQw+DKbzRZP+nji/cKi4tlsNlvS2to2AuD19ZDNZoslErE2AICoX8SjOACAq1fi9uza5b28vLzis36RSEcsFmv/GhXju8N721oAgP5+ES8vL/8fp0+f/Xnr1s3uCCE4cMAn0cjYqMHpn47n8nLznbKfZS+0nzXzChXT0tIyLynp3kaCIBgdHZ3DlixZfIwkES4UCg3T0p4s6+3tNTgS4DfH19cvobikZJaxkXED5bt7l/fyc+GRwQkJt7atXr1yL4ZhiK4XAMDOzjYj4EhwrN9hHydT06FVx0N+jhhjY/PMZMiQlw2NjXb08iRJMqRSqSYAgK6ubouOtvY7O3JBQeGckNAT4c5fzDttZja81MfX72Zm1tMlY2xsnlFl/PwDr65Zs3LPuLFjn1C2UaNGFba3dZgBAFyLi9+dm5vn9P3und9S/FATk9oA/0Nzt3vvevo47ckyX58D8+naCIJgSiVSLYQQrqOj3aGtzW3HMOytcVlaWjYjMOhYjLPz/FPmI0cUFxeXzkp/kuE2btzvOgAA1Dnq/Yd8D/4zOPinaHcPz5KDB35cwGazJbR2wLu7u43p+fftP5jk5uoSuHPn9pXR0ZcPCgQCKzrP5XK7+Hy+tUKhYDGZTDlLjSXV5fHeuh3QweVyu6wsLfJUcUOMjer19fX51DtCCIu/kbC9vKxi+vp1a3f2CoUGBgYGrzAMg+LiEvvyisppt28nbu7vF+n6+/m+Nef09XQFI0aYlajKU1v7cmJfX5/ewoXOJ6ZNm3IzKPhYjJOTYwRf0GypzuGIVq1c8cOP+w7cu3z5yj4Hh7kXKT8rK6vcgwf3LahvaBgbEBB05W5S8gZ1dY5o3Nixabt37/hWOQ+GYaCrq9tqbm5epMzxeLxWfX09Pt3G5XK7Pdw3bD167PivP/7wL1fl6zKXy+3+6KNxj0AFXrzInVf7sm6ClpZWtzI3cuSIoqZX/NEAAP39Ih0NDfU+hBDW0tJqbmo6tAYAoLWtbaSPr1/C7l3eyy/HXvthxmfT4pct+/oQh8MRAQBkZz9fgL3v6lNaWvaZmdnwMi6X+46AhobGMW1tbSMnT/4kSZnr6OwcWlxUYj97tv1lZa6tvX14eVn5dHv7Wb8tHCUlpTMAAxhrZ5cBACAUCg2ys58vcHR0iKQvrAAAt28nbmpqejVm06aNnmFh547nvMidhwH2ViVIROJaWlrdYrFYB5EIV55co22ss3d4e62+Fnd9d3Jy6jqcxpMI4RgGb+JhgGEY6e/n62hoaMAHAOjq6hqSkZHlamdnm25hMapQJpNx7iXfX/fqFX80n88fbWJiUpOfX+CAY29fT5ct+/rQsOHDKoODjkUDADCYDHnI8aNTKyurppw8FXYCkSTe0dlpqq2t3anGYknpvhx19X65XMYhFITqaw0GoKOj0y7seX164fF4bd093cYYYIjH02nr6RG+dTp2cJhz8euv3Y5UV9dMqqysmuLsPP80nS8vr5iam5fvxH/Ft+7q7h6iy+O11tTWTqK3s6amprBf1M+j27S4Wt1Hg4/MZDAYBEmSuMcmzyKSIN+51mhqagj7+kW6uFK/AADYfz4zdvm33/g0NDTa5uUXOC7+cmEona+qqv4kJyd3Hp/PH93R2WlqYKD/qqqqerLyGKCAAGHq6ur9EolUkxpJOAMnAF4vxJSfGltNMmHC+AeZmU9dent7DXg8XiuOYwQ9LoPJkItEYp5CoWAdCTg8t7SsbIadrW36iBFm5apyV1RUfmptbZWjvLkDABQXl8yiL+Z8vsDyoM+h2wghDAMMOTrOveDm5hKIYRh0dnaaVFZWTQEMQ6PMzQuNjY3q6fOisLBo9ujR1tmqvsUVF5fODP35l3AMXrf1goVfnLCztc08ciT4t7nJUeeIZDIZR1Vfaetod2z13LzBxGRIHUIATCZDzqCdZukoL6+YOmbM75snherqmkl6enrN+vp6zXQ7QghLuHlr65eLFoYqz/PKyqrJVlaWuTj+7meejo7Oob6H/BIk4t+/LdPh6rYk6B+ODpFBwcdiPp08+Q6DgStGjTIvHDZsWNWbvBAS+kt4fn6hgxqLNaC8PgAAvHdhRAiBsmA6BwDv5T+UUxVrMH962TffG1UmwTAMvY/7I386VA1sVaB95/stZmdnlymTyZBjOE7oaGt30Dkcx5GCIBgYhqHCgsI5YWfDQ0JDfpqspvb2wkhpfR/o9R3sN70shmFAEAQDx3FisH6i1emtcSIUCg0xDAO5QsHS19MTAAAMDAxo9PX16evp6TVLpVLNy7FX9/b09Bjv8PZa/T6tqrg/qe0P+1B1PgwAEL3Mm1AIr6mpnVRYWDTbxWXxUaU4gBDCGpuaxowwMyslSfK9Gv/sHKBrpNrhQ/BHeZTjvrHTbYOOr5cv6yYYGBi84vF02v+qjj/TDh/iQ/FUHbq6uoZqamoK2Wy26E19EL1OCQm3vDq7uoYuWuj8s0JBsOrq6sZfuhS7/9ixoOksFkvlfw3vXRj/H/8+4q7f2NHS3GKBM3CFh/uGrcqdnZeX73gmLDwEAMHePd9/NXLkiNL/kNQPRmrqwxWlZWUzFAqF2ratW75jMpmKkpKSmcn3U9fq6+kJ7iYlb5g4cULqDm+vVWpqLNl/Wu9fwR9NzP8rSE/PcFUoCJaq29//FiTcvL2VIBRMlyWLf1LF9/b26R0/Hnq+uKR0loaGep+drW3Gl4sXHR9tbfVisJj/Ba3fH+3UesiIAAAAAElFTkSuQmCC"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p class="s5" style="padding-top: 1pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Page <b>13 </b>of <b>58                                                                  </b><span class="p">U</span><span class="s6">pdated and reviewed by Clinical Pharmacy- Jan 2022</span></p><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:61pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cinnarizine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies. The manufacturer recommends avoiding use during pregnancy unless therapeutic benefits justify the potential risks for the fetus.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if cinnarizine is present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ciprofloxacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (Use only if no other alternatives)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:47pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cisatracurium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if cisatracurium is present in breast milk. The manufacturer recommends that caution be exercised when administering cisatracurium to breastfeeding women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cisplatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Citalopram</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clarithromycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clavulanate, potassium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clindamycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clobazam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clomiphene</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:32pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clonazepam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible*</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">*Potential toxicity if combined with other CNS depressants</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clonidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clopidogrel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Clotrimazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Colchicine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Colistimethate Sodium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Crizotinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cromolyn</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyanocobalamin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyclobenzaprine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Published information related to cyclobenzaprine use in pregnancy is limited (Flannery 1989; Moreira 2014).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyclobenzaprine is present in breast milk (Burra 2019).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyclophosphamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyclosporin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cyproterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Not indicated for use in women.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Not indicated for use in women.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Cytarabin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dacarbazine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dactinomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest High Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dantrolene Sodium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dapagliflozin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:33pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dapoxetine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies. Dapoxetine is not indicated for use in women.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if dapoxetine or its metabolites are excreted in breast milk. Dapoxetine is not indicated for use in women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Daptomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Darbepoetin Alfa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Deferasirox</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Deferiprone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Degarelix</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated in women who are or may become pregnant.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Adverse events were observed in animal reproduction</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if degarelix is excreted in breast milk. This product is not indicated for use in women.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Denosumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desferrioxamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desflurane</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desloratidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desmopressin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desogestrel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies. Discontinue therapy if pregnancy occurs. In general, the use of hormonal contraceptives, when inadvertently used early in pregnancy, have not been</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">associated with teratogenic effects.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Etonogestrel, the active metabolite of desogestrel, is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Desvenlafaxine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dexamethasone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dexlansoprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dexmedetomidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dextromethorphan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:76pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dextrose</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Appropriate use of dextrose injection would not be expected to cause adverse developmental outcomes to the fetus when used during pregnancy. Maternal hyperglycemia or malnutrition may be associated with adverse pregnancy outcomes.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Glucose is endogenous to breast milk (IOM 2005).</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diazepam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diazoxide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diclofenac</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:60pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dienogest</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated during pregnancy. Based on limited data, inadvertent exposure in pregnancy has not shown adverse effects to the fetus.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if dienogest is present in breast milk.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated in breastfeeding women. The risk of thromboembolism may be increased immediately postpartum.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Digoxin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Digoxin FAB Fragments</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(DIGIBIND)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:60pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diloxanide Furoate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Safety of diloxanide during pregnancy has not been established. Complications from intestinal amebiasis may be increased in pregnant and postpartum women (Li 1996). Use of other agents is preferred (Kappagoda 2011).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is unknown if diloxanide is excreted in human milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diltiazem</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dimethicone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Dimeticone is not absorbed systemically following oral administration.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Due to lack of systemic absorption, dimethicone is not expected to be present in breast milk.</p></td></tr><tr style="height:59pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dimethindine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse effects were not observed in animal reproduction studies. Information related to use in pregnant women is limited (Ohlinger 2003).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if dimethidene is present in breast milk, but excretion is expected. The manufacturer does not recommend use in breast-feeding women. Therapeutic use in infants &lt;1 month is contraindicated.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dimethyl Furmarate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dinoprostone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">First 28 Weeks of Pregnancy—Contraindicated Unless for</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Termination/Evacuation of Pregnancy Near or At Term— Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Probably Compatiblw</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diphenhydramine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Diphtheria Tetanus</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">acellular Pertussis (DTaP)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dipyridamole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dobesilate Calcium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Safety has not been established in pregnancy. The manufacturer recommends avoiding use</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Calcium dobesilate is present in breast milk in low concentrations (0.4 mcg/mL) after maternal intake of 1,500 mg daily. Breastfeeding is not recommended.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dobutamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Docetaxel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:45pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Domperidone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Information related to use in pregnancy is limited; effects on maternal or fetal cardiac function have not been evaluated (Choi 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Domperidone is present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Donepezil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dopamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dornase alfa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Doxazosin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Doxorubicin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Doxycycline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dulaglutide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Duloxetiene</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:97pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dupilumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Dupilumab is a monoclonal IgG antibody; IgG molecules are known to cross the placenta therefore exposure to the fetus during pregnancy may occur. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of preeclampsia, preterm birth, and low birth weight infants). Asthma should be closely monitored in pregnant women.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if dupilumab is present in breast milk; however, maternal IgG molecules are present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:75pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dutasteride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Abnormalities of external male genitalia were reported in animal reproduction studies. Use is not indicated in women. Pregnant women are advised to avoid contact with crushed or broken tablets and the semen from a male partner exposed to dutasteride.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if dutasteride is excreted in breast milk. Use is contraindicated in women of childbearing potential.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Dydrogesterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">An increased risk of adverse fetal events has not been observed in clinical trials using dydrogesterone in early pregnancy (limited data). A specific pattern of birth defects has not been observed in available case reports (Queisser-</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Luft 2009).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if dydrogesterone is present in breast milk, but likely based on experience with other progestogens.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Econazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Edoxaban</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Eletriptan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Eltrombopag</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Empagliflozin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Enalapril</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Enoxaparin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:34pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Entecavir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Contraindicated (HIV) No Human Data—Probably Compatible (Hepatitis B)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Enzalutamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ephedrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Epinephrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Epirubicin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Epoetin Alfa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Eprosartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:135pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Eptacog Alfa Factor VIIa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Pregnant patients with inherited bleeding disorders, including factor VII deficiency and Glanzmann’s thrombasthenia, may have an increased risk of bleeding following abortion, antenatal procedures, delivery, and miscarriage; close surveillance is recommended. Patients with factor VII deficiency and severe or abnormal bleeding should be treated with recombinant factor VIIa. Patients</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">with Glanzmann’s thrombasthenia and a history of bleeding can be treated prophylactically with recombinant factor</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">VIIa at delivery (RCOG [Pavord 2017).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if factor VIIa (recombinant) is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Eribulin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Erlotinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ertapenem</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Escitalopram</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Esmolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Esomeprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Estradiol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Etanercept</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Etelcalcetide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies at doses which also caused maternal toxicity</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(including hypocalcemia).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if etelcalcetide is present in breast milk. Due to the potential for hypocalcemia in a breastfeeding infant,</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ethambutol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:75pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ethamsylate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies. Etamsylate crosses the placental barrier and concentrations within cord blood are similar to maternal concentrations. There is inadequate evidence of safety in human pregnancy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Etamsylate is present in breast milk. The manufacturer recommends avoiding use in women who are nursing.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ethinylestradiol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Etomidate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Etoposide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:181pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Etoricoxib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Etoricoxib is contraindicated in women who are pregnant or who may become pregnant.</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Birth defects have been observed following in utero NSAID exposure in some studies, however data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, non-closure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Some manufacturers contraindicate etoricoxib administration with breastfeeding.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known whether etoricoxib is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Everolimus</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Evolocumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Exemestane</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ezetimibe</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:189pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Factor X (Human)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Pregnant patients with factor X deficiency may have an increased risk of bleeding following abortion, antenatal procedures, delivery, and miscarriage; close surveillance is recommended. Clotting factors should be monitored at the first antenatal visit, once or twice during the third trimester, at delivery, and prior to surgical or invasive procedures. Although factor X concentrations may increase during pregnancy, patients with severe deficiency remain at risk for bleeding. In addition, treatment may be needed if concentrations are &lt;0.3 IU/mL at term or prior to procedure. Hemostatic concentrations should be maintained for at least 3 days following procedures or</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">postpartum. When available, factor X concentrate may be used (RCOG [Pavord 2017]).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">This product is a plasma-derived, sterile, purified concentrate of human coagulation factor X. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Famciclovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fampridine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Febuxostat</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fenofibrate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fentanyl</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:135pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ferric Carboxymaltose</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Ferric carboxymaltose was not found to cross the placenta in an in vitro placental perfusion study (Malek 2010).</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Maternal iron requirements increase during pregnancy. Adequate iron concentrations to the fetus can be maintained regardless of maternal iron status, except in severe cases of anemia (IOM 2001). Untreated iron deficiency and iron deficiency anemia (IDA) in a pregnant female may be associated with adverse events, including low birth weight, preterm birth, or increased perinatal</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">mortality (ACOG 95 2008; IOM 2001; Pavord 2012).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Iron is present in breast milk (IOM 2001).</p></td></tr><tr style="height:73pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 21pt;text-indent: 0pt;text-align: left;">Ferric Hydroxide Polymaltose Complex</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use is contraindicated in the first trimester of pregnancy (contraindications may vary per region, consult local product labeling).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if ferric hydroxide polymaltose complex is present in breast milk. Iron is normally found in breast milk and maternal iron requirements are increased in breastfeeding women. The amount of iron in breast milk is generally not influenced by maternal iron status (IOM 1991).</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:309pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ferrous Sulphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Maternal iron requirements increase during pregnancy. Adequate iron concentrations to the fetus can be maintained regardless of maternal iron status, except in severe cases of anemia (IOM 2001). Untreated iron deficiency and iron deficiency anemia (IDA) in a pregnant female may be associated with adverse events, including low birth weight, preterm birth, or increased perinatal mortality (ACOG 95 2008; IOM 2001; Pavord 2012).</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">In general, treatment of iron deficiency or IDA in pregnancy is the same as in non-pregnant females. The majority of studies note iron therapy improves maternal hematologic parameters; however, information related to clinical outcomes in the mother and neonate is limited (Peña-Rosas 2015; Reveiz 2011; Siu 2015). Oral preparations are generally sufficient; however, parenteral iron therapy may be used in females who cannot tolerate or will not take oral iron, in cases of severe iron deficiency, or when malabsorption is present (ACOG 95 2008; Pavord 2012).</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Ferrous sulfate has been evaluated in multiple studies as an iron supplement or for the treatment of IDA in pregnancy (Peña-Rosas 2015; Reveiz 2011). Enteric-coated and slow/sustained-release preparations may be less effective</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(ACOG 95 2008).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Iron is present in breast milk (IOM 2001).</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Maternal iron requirements are increased in breastfeeding women (IOM 2001). Breast milk levels of iron are maintained in females with mild to moderate iron deficiency anemia (IDA), but concentrations decrease if IDA is severe (El-Farrash 2012; Kumar 2008).</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Maternal use of ferrous sulfate increases the iron content of breast milk (Marin 2012). Adverse events were not observed in breastfeeding infants following maternal use of ferrous sulfate in supplemental doses (Baykan 2006). Ferrous sulfate has been evaluated in multiple studies for the treatment of postpartum IDA (Markova 2015). The World Health Organization considers ferrous salts used for anemia to be compatible with breastfeeding (WHO 2002). All postpartum women at risk of gestational anemia (regardless of breastfeeding status) may be given oral iron with or without folic acid for 6 to 12 weeks postpartum to reduce the risk of anemia (WHO 2016c).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fexofenadine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Filgrastim</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:106pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Finasteride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use is contraindicated in females of childbearing potential. Abnormalities of external male genitalia were reported in animal reproduction studies. Pregnant females are advised to avoid contact with crushed or broken tablets.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Adequate contraception is recommended if used off-label in the management hirsutism in females associated with PCOS (ACOG 194 2018).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if finasteride is present in breast milk. Use is contraindicated in females of childbearing potential.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fingolimod</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Flavonoid Extract</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Information related to use for the treatment of hemorrhoids in pregnancy is limited. The manufacturer recommends avoiding use during pregnancy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if diosmin and hesperidin are present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Flecainide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluconazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk (≥400 mg/day)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:242pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fludrocortisone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted with fludrocortisone; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Fludrocortisone may be used to treat women during pregnancy who require therapy for congenital adrenal hyperplasia or primary adrenal insufficiency (Endocrine</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Society [Bornstein 2016; Speiser 2018]).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if fludrocortisone is excreted in breast milk; corticosteroids are excreted in breast milk. The manufacturer recommends that caution be exercised when administering fludrocortisone to nursing women.</p></td></tr><tr style="height:45pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Flunarizine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if flunarizine is excreted into breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluorouracil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:31pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluorescein Sodium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Limited Human Data—Potential Toxicity (IV) Limited Human Data—Probably Compatible (Topical)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluoxetine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluticasone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:104pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 34pt;text-indent: 0pt;text-align: left;">Fluticasone, Umeclidinium, and</p><p class="s2" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Vilanterol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted with this combination. Refer to individual monographs.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if sufficient quantities of fluticasone, umeclidinium, or vilanterol are absorbed systemically following inhalation to produce detectable amounts in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Also refer to individual monographs.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluvastatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated 1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fluvoxamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Folic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:108pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Follitropin alpha</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics). Follitropin Alfa is used for the induction of ovulation; use is contraindicated</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">in women who are already pregnant.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">It is not known if follitropin alfa is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fondaparinux</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Formoterol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fosfomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fulvestrant</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Furosemide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:127pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Fusidic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse effects were not observed in animal reproduction studies. Fusidic acid crosses the placenta following systemic administration. Systemic absorption following topical application is minimal.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if fusidic acid is present in breast milk following topical application.</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Fusidic acid is present in breast milk following systemic administration; however, systemic absorption following topical application is minimal. Topical fusidic acid has been evaluated for Staphylococcus aureus impetigo infection in breastfeeding patients with sore, cracked nipples; fusidic acid was not effective for systemic infection that may lead to mastitis (Livingstone 1999).</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gabapentin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:227pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gadoterate Meglumine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Gadolinium-based contrast agents may cross the placenta (ACOG 723 2017; ACR 2018).</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 723 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2018).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Gadolinium-based contrast agents may be present in breast milk (ACOG 723 2017; ACR 2018).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Because of the low expected excretion into breast milk and the low absorption from an infant&#39;s GI tract, breastfeeding may be continued without interruption after use (ACOG 723 2017; ACR 2018). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2018). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ganciclovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gatifloxacin, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gemcitabine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gemfibrozil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:150pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 48pt;text-indent: 0pt;text-align: left;">Glecaprevir and Pibrentasvir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies with glecaprevir or pibrentasvir as individual agents. Treatment of hepatitis C is not currently recommended to treat maternal infection or to decrease the risk of mother-to-child transmission during pregnancy (Tran 2016). When HCV infection is detected during pregnancy, treatment should be deferred until after delivery. Direct-acting antiviral medications should not be used in pregnant females outside of clinical trials until safety and efficacy information is available (SMFM [Hughes 2017]).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">It is not known if glecaprevir or pibrentasvir are present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p><p class="s3" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Breastfeeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breastfeeding is not recommended (milk should be expressed and discarded).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Breastfeeding is not recommended in the presence of HIV co-infection (AASLD/IDSA 2018; SMFM [Hughes 2017]).</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:175pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Gliclazide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Gliclazide is contraindicated for use during pregnancy. Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2020; Blumer 2013). Agents other than gliclazide are currently recommended to treat</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">diabetes mellitus in pregnancy (ADA 2020).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 52pt;text-indent: 0pt;text-align: left;">It is not known if gliclazide is present in breast milk. Use is contraindicated in breastfeeding mothers.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Glimepiride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Glucagon</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:110pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Glutamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Endogenous glutamine can be detected in cord blood and concentrations are decreased in low birth-weight infants (Ivorra 2012).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">The manufacturer recommends that caution be exercised when administering glutamine to breastfeeding women. Glutamine is endogenous to breast milk. The amount of total protein and free amino acids found in breast milk varies during lactation (IOM 2005). Effects of the suggested oral dose of glutamine are unknown.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Glycopyrrolate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:31pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Golimumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk Contraindicated (if combined with methotrexate)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Probably Compatible Contraindicated (if combined with methotrexate)</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:256pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Goserelin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Goserelin induces hormonal changes which increase the risk for fetal loss and use is contraindicated in pregnancy unless being used for palliative treatment of advanced breast cancer.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Breast cancer: If used for the palliative treatment of breast cancer during pregnancy, the potential for increased fetal loss should be discussed with the patient.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Endometriosis, endometrial thinning: Use is contraindicated during pregnancy. Women of childbearing potential should not receive therapy until pregnancy has been excluded.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Nonhormonal contraception is recommended for premenopausal women during therapy and for 12 weeks after therapy is discontinued. Although ovulation is usually inhibited and menstruation may stop, pregnancy prevention is not ensured during goserelin therapy.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Changes in reproductive function may occur following chronic administration.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">It is not known if goserelin is present in breast milk, although goserelin is inactivated when used orally. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:26pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Granisetron</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Haloperidol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Heparin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hepatitis A Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hepatitis B</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Immunoglobulin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hepatitis B Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:128pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 41pt;text-indent: 0pt;text-align: left;">Human Chorionic Gonadotrophin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Studies in animals have shown evidence of fetal abnormalities at doses intended to induce superovulation (used in combination regimens).</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">When needed for ovulation induction, should only be used by physicians who are thoroughly familiar with infertility problems and their management. Multiple births may result from use of this medication.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Testicular tumors in otherwise healthy men have been reported when treating secondary infertility.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if chorionic gonadotropin (human) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering chorionic gonadotropin (human) to breastfeeding women.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Papilloma Virus</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(Types 16,18) Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:59pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 21pt;text-indent: 0pt;text-align: left;">Human Prothrombin Complex Concentrate [(Factors II, VII, IX, X),</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Protein C, and Protein S]</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">This product is derived from purified human plasma.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">It is not known if prothrombin complex concentrate is present in breast milk. The manufacturer recommends that prothrombin complex concentrate be administered only if clearly needed when treating a breastfeeding woman.</p></td></tr><tr style="height:113pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hyaluronidase</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse maternal or fetal events were not observed when used as an aid to delivery or an aid to conception.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Administration during labor did not cause any increase in blood loss or differences in cervical trauma.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Hyaluronidase has been evaluated for use prior to intracytoplasmic sperm injection (ICSI) to aid the in vitro fertilization of human eggs (DeVos 2008; Evison 2009; Majumdar 2013; Moura 2017; Worrilow 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if hyaluronidase is present in breast milk following therapeutic administration.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydralazine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydrocortisone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydromorphone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydroquinone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydroxychloroquine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydroxyprogesterone</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Caproate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk (0–16 weeks) Compatible (after</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">16 weeks)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hydroxyurea</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hyoscine butylbromide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ibandronate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ibrutinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ibuprofen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in the 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:45pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Idarucizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Animal reproduction studies have not been conducted.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 27pt;text-indent: 0pt;text-align: justify;">It is not known if idarucizumab is present in breast milk. The manufacturer recommends that caution be exercised when administering idarucizumab to breastfeeding women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ifosfamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Imatinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Imipenem/Cilastatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:104pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Inclisiran</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action, in utero exposure to inclisiran may cause fetal harm. Inclisiran should be discontinued as soon as pregnancy is recognized.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if inclisiran is present in breast milk.</p><p class="s3" style="padding-top: 4pt;padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Inclisiran has poor oral absorption, therefore, if present in breast milk it is unlikely to impact infant development. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Incobotulinumtoxin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Indapamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Infliximab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Human Data Suggest Low Risk (Contraindicated if Combined with Methotrexate)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Influenza Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Aspart</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Degludec</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Detemir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Glargine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Glulisine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:282pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin, Isophane</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2020; Blumer 2013).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2020).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus, when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2020). NPH insulin</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">may be used to treat diabetes mellitus in pregnancy (ACOG</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">190 2018; ACOG 201 2018; Blumer 2013)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Breastfeeding is encouraged for all females, including those with type 1, type 2, or gestational diabetes mellitus (ACOG 201 2018; ADA 2020; Blumer 2013). A small snack before breastfeeding may help decrease the risk of hypoglycemia in females with pregestational diabetes (ACOG 201 2018; Reader 2004).</p></td></tr><tr style="height:19pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin Lispro</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Insulin, Soluble</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Interferon Beta</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Intravenous</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Immunoglobulin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:135pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Iobitridol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use of iobitridol for hysterosalpingography is contraindicated in pregnant women. Fetal dysthyroidism may occur with iobitridol use within 14 weeks of amenorrhea. In general, use of iodinated contrast media should not be withheld if required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2016).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Small amounts of iobitridol are present in breast milk. Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant’s GI tract, breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2016). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2016). Manufacturers recommend avoiding</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">breast-feeding for 24 hours after administration.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ipratropium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Irbesartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Irinotecan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:162pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 40pt;text-indent: 0pt;text-align: left;">Iron Isomaltoside (Monofer)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Fetal bradycardia has been observed following maternal administration (Woodward 2015).</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Iron requirements are increased in pregnant women compared to non-pregnant women. Untreated iron deficiency anemia during pregnancy may be associated with an increased risk of adverse pregnancy outcomes (IOM 2001). The manufacturer recommends iron deficiency anemia in the first trimester be treated with oral iron, the injection formulation may be considered for the second and third trimesters. Iron isomaltoside has been evaluated for use following postpartum hemorrhage (Holm 2017a, Holm</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">2017b).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Iron isomaltoside is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Following maternal administration of a single dose of iron isomaltoside immediately postpartum, the mean breast milk concentrations of iron remained within normal limits (Holm C 2017c). Iron is normally found in breast milk and maternal iron requirements are increased in breastfeeding women. The amount of iron in breast milk is generally not influenced by maternal iron status (IOM 1991).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Isoniazid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Isoprenaline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Isosorbide Dinitrate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Isotretenoin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Itraconazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ivabradine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ixekizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ixekizumab is a humanized monoclonal antibody (IgG4).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Placental transfer of human IgG is dependent upon the IgG</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if ixekizumab is present in breast milk.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ketamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ketoconazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk (Oral) No Human Data—Probably Compatible (Topical)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Labetalol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lacosamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lactulose</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lamivudine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (HIV) Compatible (Hepatitis B)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lamotrigine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lanreotide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lansoprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lapatinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Latanoprost, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ledipasvir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Leflunomide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lenvatinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:59pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lercanidipine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated in women who are pregnant or may become pregnant (unless effective contraception is used). If treatment for hypertension during pregnancy is needed, other agents are preferred (Mancia 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated in breastfeeding women. It is not known if lercanidipine is present in breast milk. According to the manufacturer, distribution into milk may be expected due to the high lipophilicity of lercanidipine.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Letrozole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levetiracetam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levocabastine, Nasal</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in some animal reproduction studies when using oral doses much larger than the equivalent maximum human nasal dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Following intranasal application, minute amounts of levocabastine have been detected in human breast milk (Simons 1999). The manufacturer recommends that caution be exercised</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">when administering levocabastine to nursing women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levocetirizine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levodopa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levofloxacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (Use only if no other alternatives)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levonorgestrel (IUD)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use during pregnancy or a suspected pregnancy is contraindicated.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levonorgestrel is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Levothyroxine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lidocaine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Linaclotide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Linagliptin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Linezolid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Liothyronine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Liraglutide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lisinopril</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lithium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:174pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lixisenatide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2019; Blumer 2013).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Agents other than lixisenatide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2019).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if lixisenatide is present in breast milk.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:131pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Lonsurf (Trifluridine/Tipiracil)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to trifluridine/tipiracil may cause fetal harm.</p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Verify pregnancy status in females of reproductive potential prior to therapy initiation. Females of reproductive potential should use effective contraception during therapy and for at least 6 months after the final trifluridine and tipiracil dose. Males who have female partners of reproductive potential should use condoms during therapy and for at least 3 months following the final dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if trifluridine or tipiracil are present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for one day following the last dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Loperamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Loratadine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lorazepam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible, but potential</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">toxicity if combined with other CNS depressants</p></td></tr><tr style="height:262pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lornoxicam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Some manufacturers contraindicate lornoxicam use in all trimesters of pregnancy; some contraindicate use in the 3rd trimester (consult local product labeling).</p><p class="s4" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, non-closure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p><p class="s4" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bermas 2014; Bloor 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if lornoxicam is present in breast milk. Breastfeeding is not recommended by the manufacturers</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Losartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:94pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Loxoprofen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Medication should be administered to women who are or are possibly pregnant only when the anticipated therapeutic benefits are considered to outweigh any potential risk. (The safety of this ROXONIN in these populations has not been established).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It should not be used in women in the late stages of</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">pregnancy</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;text-align: justify;">Administration of this medication to nursing mothers should be avoided. If administration of this drug is judged to be essential, nursing should be discontinued.</p></td></tr><tr style="height:135pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Lutropin alfa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: justify;">Use is contraindicated in women who are pregnant or those who have medical conditions which are incompatible with a normal pregnancy.</p><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Ectopic pregnancy, miscarriage, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after assisted reproductive techniques than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use in breastfeeding women is contraindicated per the manufacturer labeling.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if lutropin alfa is present into breast milk.</p></td></tr><tr style="height:99pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Magnesium Citrate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002). The American Gastroenterological Association considers the use of magnesium citrate as a laxative to be low risk in pregnancy, but long term use should be avoided (not the preferred treatment of chronic constipation) (Mahadevan 2006).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Magnesium Oxide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">requirements are the same in lactating and nonlactating females (IOM,1997).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Magnesium Sulphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mannitol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Measles Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mebendazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible (2nd &amp; 3rd Trimesters)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:45pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mebeverine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">The manufacturer recommends avoiding use during pregnancy (limited data available).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if mebeverine or its metabolites are present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Meclizine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:90pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mecobalamin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Methylcobalamin (or mecobalamin) is a biologically active form of vitamin B12. Vitamin B12 and its active coenzymes cross the placenta (Craft 1971). Vitamin B12 requirements may be increased in pregnant women compared to nonpregnant women (IOM 1998).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Methylcobalamin (or mecobalamin) is a biologically active form of vitamin B12. Vitamin B12 and its active coenzymes can be detected in breast milk (Craft 1971). Vitamin B12 requirements may be increased in nursing women compared to non-nursing women (IOM 1998).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Medroxyprogesterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mefenamic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mefloquine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:229pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Megestrol Acetate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Use is contraindicated for the treatment of anorexia or cachexia in pregnant females with HIV infection.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Megestrol may cause fetal harm if administered during pregnancy.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Evaluate pregnancy status prior to treatment in females of reproductive potential. Effective contraception should be used when treating anorexia or cachexia in females with HIV infection. In clinical studies, megestrol was shown to cause breakthrough vaginal bleeding in women.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Megestrol is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Information is available from 5 breastfeeding women, 8 weeks postpartum, who were administered megestrol 4 mg in combination with ethinyl estradiol 50 mcg daily for contraception. Maternal serum and milk samples were obtained over 5 days, beginning 10 days after therapy began. The highest concentrations of megestrol were found at the samples taken 3 hours after the maternal dose. Mean concentrations of megestrol were 6.5 ng/mL (maternal serum; range: 3.7 to 10.8 ng/mL), 4.6 ng/mL (foremilk; range: 1.1 to 12.7 ng/mL), and 5.6</p><p class="s3" style="padding-left: 5pt;padding-right: 17pt;text-indent: 0pt;text-align: left;">ng/mL (hindmilk; range: 1.2 to 18.5 ng/mL) (Nilsson 1977). Due to the potential for adverse reaction in the breastfed newborn, the manufacturer recommends discontinuing breastfeeding while receiving megestrol for the treatment of</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">cancer. Due to the potential for HIV transmission, breastfeeding is not recommended when treating females for anorexia or</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">cachexia associated with HIV infection.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Meloxicam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:76pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Memantine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">It is not known if memantine is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Meningococcal Vaccine</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">ACYW-135</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:136pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Menotropin (hMG)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multi-fetal gestations/births have been reported. The incidence of congenital abnormality may be slightly higher after assisted reproductive technology (ART) than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, genetics, and sperm characteristics). Menotropins are used for the induction of ovulation and with ART; use is contraindicated in women who are already pregnant.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Pregnancy should be excluded prior to treatment.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if menotropins is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mepolizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Meropenem</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mesalazine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mesna</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Metformin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methotrexate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:120pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 20pt;text-indent: 0pt;text-align: left;">Methoxy-PEG Epoetin Beta</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in some animal reproduction studies. Information related to the use of methoxy polyethylene glycol-epoetin beta during pregnancy is limited.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">It is not known if methoxy polyethylene glycol-epoetin beta is present in breast milk; however, endogenous erythropoietin is found in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:20pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methyldopa</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methylene blue</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methylergometrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methylphenidate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:175pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Methylprednisolone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;line-height: 14pt;text-align: left;">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Götestam Skorpen 2016; Makol 2011; Østensen 2009).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Methylprednisolone is present in breast milk (Cooper 2015; Strijbos 2015), the manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Metoclopramide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Metolazone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Metoprolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Metronidazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding (Single Dose)</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Limited Human Data—Potential Toxicity (Divided Dose)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Miconazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible (Topical)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:28pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Midazolam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible*</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">*Potential Toxicity If Combined With Other CNS Depressants</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Midodrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Milrinone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Minoxidil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mirabegron</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mirtazapine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Misoprostol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (Oral)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mitomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest High Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mitoxantron</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Modafinil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mometasone, Topical</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Montelukast</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Morphine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Moxifloxacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (Use only if no other alternatives)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:60pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Moxonidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been reported in animal reproduction studies in doses associated with maternal toxicity; the manufacturer recommends avoiding use during pregnancy unless clearly necessary.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Moxonidine is present in breast milk in concentrations 50% to 100% greater than those in the maternal serum (Kirsten 1998). Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mumps Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mupirocin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Mycophenolate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">N-acetylcysteine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefits &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Naloxone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Naphazolin, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Naproxen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Natalizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nebivolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Neostigmine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nicorandil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Use is not recommended</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Use is not recommended in breastfeeding women</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nifedipine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nimodipine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nintedanib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nitrofurantoin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nitroglycerin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nivolumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nizatidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Noradrenaline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Norethisterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:109pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Norfloxacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in some animal reproduction studies. Norfloxacin crosses the placenta, distributing to cord blood and amniotic fluid (Wise 1984). Based on available data, an increased risk of teratogenic effects has not been observed following norfloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Norfloxacin was not detected in the milk of nursing mothers administered an oral 200 mg dose. It is not known if concentrations would be detectable after a higher dose or multiple doses. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Nystatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Obinutuzumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:270pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ocrelizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Information related to the use of ocrelizumab in pregnancy is limited (Fragoso 2018; Juanatey 2018). Transient peripheral B-cell depletion and lymphocytopenia have been observed in infants born to mothers who received similar agents; immune response to live or live-attenuated vaccines may be decreased in infants exposed to ocrelizumab in utero. Evaluate immune response by measuring CD19+B-cells in exposed infants prior to the administration of live or live-attenuated vaccines.</p><p class="s4" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy, and not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). Consider use of agents other than ocrelizumab for females at high risk of disease reactivation who are planning a pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Females of reproductive potential should use effective contraception during therapy and for 6 months after the last ocrelizumab infusion.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if ocrelizumab is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">The potential for B-cell depletion in a breastfed infant following maternal use of ocrelizumab is not known. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Other sources do not recommend breastfeeding during therapy (Dobson 2019; Fragoso 2018).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Octereotide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ofloxacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (Use only if no other alternatives)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Olanzapine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Olaparib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Olmesartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Olopatadine, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Omalizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Omega-3 Fatty Acid</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Supplements</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Omeprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ondansetron</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oral Contraceptives</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Orlistat</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oseltamivir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:135pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Osimertinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on data from animal reproduction studies and the mechanism of action, use during pregnancy is expected to cause fetal harm. Verify pregnancy status in females of reproductive potential prior to initiating osimertinib.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Females of reproductive potential should use effective contraception during therapy and for 6 weeks after the last osimertinib dose. Males with female partners of reproductive potential should also use effective contraception during therapy and for 4 months after the</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">last osimertinib dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if osimertinib (or its active metabolites) are present in breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 2 weeks after the last osimertinib dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oxaliplatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (1st Trimester)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oxcarbazepine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oxycodone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:101pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Oxytocin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">[US Boxed Warning]: To be used for medical rather than elective induction of labor.</p><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Small amounts of exogenous oxytocin are expected to reach the fetal circulation. When used as indicated, teratogenic effects would not be expected. Nonteratogenic adverse reactions are reported in the neonate as well as the mother.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Endogenous oxytocin mediates milk ejection. Administration of exogenous oxytocin may disrupt the initiation of breastfeeding (Buckley 2015). Skin-to-skin contact between mother and baby facilitates the release of endogenous oxytocin and the establishment of the milk ejection reflex (ABM 2011).</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Paclitaxel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Palbociclib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Palivizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Palonosetron</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Panitumumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pantoprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Papaverine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Teratogenic effects have not been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if papaverine is excreted in breast milk. The manufacturer recommends that caution be exercised when</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">administering papaverine to nursing women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Paracetamol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:155pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Parecoxib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Parecoxib is contraindicated for use in the third trimester of pregnancy.</p><p class="s4" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Birth defects have been observed following in utero NSAID exposure in some studies, however data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, non-closure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 38pt;text-indent: 0pt;text-align: left;">Parecoxib use is contraindicated with breastfeeding. Small amounts of parecoxib are present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Paricalcitol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Paroxetine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:50pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Patiromer</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Patiromer is not absorbed systemically following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Patiromer is not absorbed systemically following oral administration. Breastfeeding is not expected to result in significant exposure to a breastfed child.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pazopanib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pegfilgrastim</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Peginterferon Alfa 2A</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Peginterferon Beta-1a</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pembrolizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:31pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pemetrexed</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 61pt;text-indent: 0pt;text-align: left;">Contraindicated—1st Trimester Contraindicated (if Combined with Cisplatin)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated (if Combined with Cisplatin)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Penicillin G, Benzathine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pentoxifylline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 3pt;text-indent: 0pt;text-align: left;">Perflutern Protein –Type A (Optison)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Due to the very short half-life, administration during pregnancy is not expected to result in clinically relevant</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">fetal exposure.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if perflutren lipid microspheres is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Perindopril</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Permethrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Permpanel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pertuzumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pethidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phenobarbital</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phentermine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phentolamine Mesylate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phenylephrine,</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phenytoin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phytomenadione</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pilocarpine, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pimecrolimus</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:86pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pinaverium Bromide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Animal reproduction studies are insufficient and information from human pregnancies is not available. The presence of bromine in the formulation poses a theoretical risk of causing neurologic effects (sedation, hypotony) to newborns if pinaverium is used late in pregnancy, though no such cases have been reported.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Manufacturer advises against administration in breast-feeding women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pioglitazone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pipracillin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:81pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Piracetam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies. Piracetam crosses placental barrier with neonatal levels ~70% to 90% of maternal levels. In general, higher risk of teratogenic effects may be associated with anticonvulsant polytherapy compared to</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">monotherapy (Morrow, 2006).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Piracetam is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pirfenidone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:60pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Piribedil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Information related to the use of piribedil in pregnant women has not been located. If treatment for Parkinson disease in pregnancy is needed, agents other than piribedil may be preferred (Kranick 2010).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if piribedil is excreted in breast milk. Piribedil has been shown to inhibit lactation (Alagna 1979). Use in breastfeeding women is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Piroxicam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 1st and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:81pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pizotifen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies. If possible, drug therapy for migraine prophylaxis should be avoided during pregnancy. If therapy is needed, other agents are preferred</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">The concentration of pizotifen measured in the milk of nursing mothers is unlikely to affect a nursing infant; however, the manufacturer does not recommend use in nursing mothers. If possible, drug therapy for migraine prophylaxis should be avoided in nursing women. If therapy is needed, other agents</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">are preferred</p></td></tr><tr style="height:103pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 9pt;text-indent: 0pt;text-align: left;">Pneumococcal 10-valent Conjugate Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: justify;">Animal reproduction studies have not shown adverse fetal effects. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering this vaccine to breastfeeding women.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></td></tr><tr style="height:76pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Policresulen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Manufacturers advise against use of policresulen in pregnancy. Adverse events were not observed in animal reproduction studies. Swabbing the endocervix should be avoided in pregnant women. Cauterization of the cervix should be avoided as it may induce labor.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Manufacturers advise against use of policresulen with breastfeeding. It is not known if policresulen is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Polidocanol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Poliovirus Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse effects of bOPV have not been documented in pregnant women. Pregnant women at increased risk for infection with wild polioviruses may be administered the vaccine (WHO 2016).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Females of child-bearing potential should use contraception for 3 months following vaccination.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">The effects of administering bOPV to breastfeeding mothers on breast-fed infants is unknown. Infants receiving vaccine may be breast fed; however, administration should be separated by 2 hours before or after vaccination to avoid contact with antibodies present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Polyethylene Glycol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:108pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Potassium Acetate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia)</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(IOM 2004).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Potassium is excreted into breast milk (IOM 2004).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Potassium Chloride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:121pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Potassium Phosphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Phosphorus requirements are the same in pregnant and nonpregnant women (IOM 1997). Although this product is not used for potassium supplementation, adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">develop hyperkalemia) (IOM 2004).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Potassium is excreted into breast milk (IOM 2004). Phosphorus, sodium, and potassium are normal constituents of human milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pralidoxime</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo/Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pramipexole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Prasugrel</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Prednisolone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pregabalin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Primidone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Procainamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAUYAAAAICAYAAACF8lZYAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAASe0lEQVRoge1Zd1RU17r/zpkZZigDQxdRFCkiaCyJsUQlKlyuBjUKJJrYNQoqilhyNbGAAgIaIbGhIBpAURGxICJYkKKI9N6kOUMvA0xhZs7Z7w89yXEcjMl9efet9d5vrbPWnO+3v+/77b73GUAIgaqHJEnw8w+MdXFd2uXqtrSzvb1jKEII7ty5656Xlz+XKldVVT0pKvrSAZIk4ebN21vy8gt+45pbWkaeP3/BnyRJSE5OWf047clXFMcXCEZFRl70I0kS6LFu3Li5jW77qw9BEHhFReVkeiySJH97qHzx8Qle/26uN/mwlNQHK9LS0t3q6xts/zti/h1PfHyCV8yl2B/b29tNpVIp58SJUycGa2+BQDDq4cPHy1JSH6wgCAL7u7XdSby7MSoq5kBra9twmUym9ssvp04Opq2lpWXEg4ePvrmfkrqSIAhceezKZDK1svKKKdfjE7wCg45G+fr6XZfL5UyqTErqgxWlpWXTPlRbb2+v7uHDAdcePUpbSmlqaGi0iYqOOaCqvEQi0djovrnIxXVp15q131XTcycmJm2Ii4vfMdg4irt+w/vFi9x/KNeprLx8ikgk4tLt7e3tpvv3+9ySSCSaquKRJAlNTU3Wra2tZlKplPN39V1W1tOFLq5Lu11cl3ZFRf3eJv39/dq+h/yut7W1DaNsPT1C/YjzFwKodiRJEk6fOXuc0ieTyVlbt3lnu7gu7frm21WvJBKJxv/E3KA/OAwCkiQZNTU1H8+f/8+ws2GnbA0M9AUAAPn5BQ7hEZHBCCEMIQQXL0b5ZWY+XQwAWEFh4ZwzZ86GkiSJI4QgOvrSwZwXufMBALKyni4+f/7iEYVCwUQIQXTUJZ/nOa+5N/nw4yE/n7/4a/Thjo6OYYPp+lCIxWJudvbzBX19fXqULSHhlpePr19CQEDQFZlMxk5MTNrEFwislH3fdBb2Z3NytbS6uVytrq7u7iH/rv6/CxKpVCs5OWUdhuHk02fZi9IzstxIEqkcBxwOpx9n4AomgyGXSqVaf7c2mUzOSb6fsg4BwnJe5M578PDRSoVCwVJVls3miBk4Q8FisQYkEgmXsiOE4Oq169+vXbex5t695O94Ojrti79cFOLt7bWGyWQqqHJhYeEhAwMDmh+qDcMwsqCwcE5Nbe1EDHs9NK5cjdtTV9cwTlV5obDXsLGxyXbvnu+/Cjl+dCo9d0dH57BLl6/sIwiCSfcRiUTa2713PVXncPrHj//oEZ17kp7x1eHDAfE+vn4JCKHf7AwGU15YVDwnK+vpl6p0IISw9PRMt5TUhyvT0tKXfWh9/yyqqmom83i81rAzJ+zc3FwC6fpqamon3bx1x5Oy1dXVjY+Li99VWVX9KQBAbm6e061bd7a2traZAwCIRP28+vr6cV5enutPngidwOFwxH+X7sGANzQ02jU3N4+iNzYAAIPBIKZOnXKzorxiqq6ubitl9/DY6MnnC6wfPnz8bXFxiX1efoHjtq2bN2AYhrZs3uTR3tZulpiY5N7Y2GT7+PGTbzZv8tiEYRh4em5yFwqFRrdvJ26pr68f9yQ94+stm903UYMsLi5+p1Qq1Zw+beqN06fP/qKshwK1olO/B4O6unq/paVFXlVV9acIIQwAwNl5/sntXp7r169fu1NNTW1gMN/k5JR17h5bSp49e+5MEASDzpEkiQkEzRZpaelfvdWQOI4+/njSvdTUh6v0dHVblDXT47S1tw+ndniKHxgYUFdejBFC8CQ9wzUgICh2z959Kb6H/ON7enoMlfVSGxHlQ5IkriovAICVpUWuvr6eQF9fr9nI0LBJIpFoMRg4qaodeDxemy5Pt7W0rHyGhoZG32DtRYHa9AYDQRCMqKiYg/sP+N7Zs3dfSlR0zEE6bzHKvIDH47UaGxk1GhsZNQwMDKgzGAyFqlg6OtrtBoYGr4qKimdramoK6dyzZ9kLBwakGpMmTbw/e7b9JSsry1xNTY3eP9IP8Lp/ZTIZWyaTcahxAwCgpaUlNDU1rTY3H1lM2YYPM61kMZlyVXGMjY0abMeMyaqprZ2kra3dSecWL174k1gs1hYIBBZ0e15egWNDQ+PY/PwCB7lcrkbZZTK52pUr1/acOXPSbqjJkNrSsvLPKE5Xl9c247Pp1wsLi2er0oHjOJo1a+ZVHR2djpmzZlxR7p+y8vJpCoWCqez3+uQmY6viVOHzz2de5vP51ggBxmazpZSdw2FL5s+fF1ZTU/sxZRs//qOHn9vPig0PP3+UJEk88sKvAYsWLQg1MxteDgDA4/HaJ0wYn1pdXfMJj6fToSrf+9YH5TH/IXh9ypdqVlZWTZZIJJr4yZOnTwQcCb5CTSY6rK0sXwzIZBp0m76+XvPaNau+j7zwa8CFi1F+CxZ8cdLGZvRzAAA9Pd3Wje7fbbv4a5RfeMT5ow5z51y0tbXJeu2n37xxw/rtMZdiD4RHRAY7Os6NHDPG5ikAQHNzi3l0zGWf1atW7l29esXe5zkv5j99lr1IVQXi4xN2xF65thcAoKSkdKaqMmKxmLtn777U/PxCBz//I9fq6urHAgCwWCx5V1e3yXbvnc+6u3uMVPk+fPT4m7t377mLxRLto8d+ivLesTurvf33E2xERGTwmbBzodOnT034PZ9E68aNm1579+5PLSktnZn9PMeZHjMxMcnd3z/wKvV+PS5+1/IVa/iZmU+XkCSJnQk7F7p23YaaU6fCTtI7vEcoNEpIuLU9PSPT1dx8ZNHz5zlfSKXvnnICA49eqq19OREAIDs7Z0F4RGQQQgjup6Su2bfPJ4le1tDQsLGzo9P0zStC6N3TIkIIq66u/tg/IPDqpcux+1NSHqyWy+UsGg9lZeXT6WNGKpWqe2zyLCooLJwLACCTydh9/f08etyi4hL7xLv3PIqLS+zNhg8vKykpe6v/DA0NGzs7O03ftAFCCDEA4J3NoqamdsKRwODY6OgYn9TUh6sHZDIOxWMYBsFBAZ8HBQXYR0REBh8P+TlcJpOxleuoCn19/bxDh/xvuHtsKVm5al19Tk7uPDo/dKhJdUtLqzn1zmQy5T1C4TsbFYXRNtbZAoHAUtnO5XJ7DAwMmkQi8VvtM2PG9OsrVy7/kSAJFs5gEJT97t0kdycnx/NcLa0ec3PzIgFfYE33s7K2etEvEumq0oAQghMnT59qFjRbbN68tTAxMcmDzsfHJ+wICf0lXHlTzszMWrJli1f+mrUbaiMiIgP5fL6VVCrVIAiCoWpRMjMzK9PT1W3u7u4yUeZGjjArEYvEOtQ7hmHg4bHBs76+YWxg0NGYnp4e41Url/9I97EZPTq7WdBsoRwLAEAqlWq8fFk3QRWXkvJgzQ8/7L+vqh0oDAwMcPLy8h0BXm/WjY1NNoGBRy+HhZ0LuX79xs7Va76rYwYEHHYgCILFYDDeOTWw2RzJGJvXCxsdzs7zT6c9SV/a2tpqHuB/yJHOOTrMvZCZkeVaXlE5LTLynDl1IgQAcHJyDM/IzHKprq755Ie9/3KjuHPh549ZWIzKmzFjehyO4+iLL+adOXcu4qepUz69heP4W70wb57TWZlMzgEAiIqKObRtm+d6ptKufSQw+DKbzRZP+nji/cKi4tlsNlvS2to2AuD19ZDNZoslErE2AICoX8SjOACAq1fi9uza5b28vLzis36RSEcsFmv/GhXju8N721oAgP5+ES8vL/8fp0+f/Xnr1s3uCCE4cMAn0cjYqMHpn47n8nLznbKfZS+0nzXzChXT0tIyLynp3kaCIBgdHZ3DlixZfIwkES4UCg3T0p4s6+3tNTgS4DfH19cvobikZJaxkXED5bt7l/fyc+GRwQkJt7atXr1yL4ZhiK4XAMDOzjYj4EhwrN9hHydT06FVx0N+jhhjY/PMZMiQlw2NjXb08iRJMqRSqSYAgK6ubouOtvY7O3JBQeGckNAT4c5fzDttZja81MfX72Zm1tMlY2xsnlFl/PwDr65Zs3LPuLFjn1C2UaNGFba3dZgBAFyLi9+dm5vn9P3und9S/FATk9oA/0Nzt3vvevo47ckyX58D8+naCIJgSiVSLYQQrqOj3aGtzW3HMOytcVlaWjYjMOhYjLPz/FPmI0cUFxeXzkp/kuE2btzvOgAA1Dnq/Yd8D/4zOPinaHcPz5KDB35cwGazJbR2wLu7u43p+fftP5jk5uoSuHPn9pXR0ZcPCgQCKzrP5XK7+Hy+tUKhYDGZTDlLjSXV5fHeuh3QweVyu6wsLfJUcUOMjer19fX51DtCCIu/kbC9vKxi+vp1a3f2CoUGBgYGrzAMg+LiEvvyisppt28nbu7vF+n6+/m+Nef09XQFI0aYlajKU1v7cmJfX5/ewoXOJ6ZNm3IzKPhYjJOTYwRf0GypzuGIVq1c8cOP+w7cu3z5yj4Hh7kXKT8rK6vcgwf3LahvaBgbEBB05W5S8gZ1dY5o3Nixabt37/hWOQ+GYaCrq9tqbm5epMzxeLxWfX09Pt3G5XK7Pdw3bD167PivP/7wL1fl6zKXy+3+6KNxj0AFXrzInVf7sm6ClpZWtzI3cuSIoqZX/NEAAP39Ih0NDfU+hBDW0tJqbmo6tAYAoLWtbaSPr1/C7l3eyy/HXvthxmfT4pct+/oQh8MRAQBkZz9fgL3v6lNaWvaZmdnwMi6X+46AhobGMW1tbSMnT/4kSZnr6OwcWlxUYj97tv1lZa6tvX14eVn5dHv7Wb8tHCUlpTMAAxhrZ5cBACAUCg2ys58vcHR0iKQvrAAAt28nbmpqejVm06aNnmFh547nvMidhwH2ViVIROJaWlrdYrFYB5EIV55co22ss3d4e62+Fnd9d3Jy6jqcxpMI4RgGb+JhgGEY6e/n62hoaMAHAOjq6hqSkZHlamdnm25hMapQJpNx7iXfX/fqFX80n88fbWJiUpOfX+CAY29fT5ct+/rQsOHDKoODjkUDADCYDHnI8aNTKyurppw8FXYCkSTe0dlpqq2t3anGYknpvhx19X65XMYhFITqaw0GoKOj0y7seX164fF4bd093cYYYIjH02nr6RG+dTp2cJhz8euv3Y5UV9dMqqysmuLsPP80nS8vr5iam5fvxH/Ft+7q7h6iy+O11tTWTqK3s6amprBf1M+j27S4Wt1Hg4/MZDAYBEmSuMcmzyKSIN+51mhqagj7+kW6uFK/AADYfz4zdvm33/g0NDTa5uUXOC7+cmEona+qqv4kJyd3Hp/PH93R2WlqYKD/qqqqerLyGKCAAGHq6ur9EolUkxpJOAMnAF4vxJSfGltNMmHC+AeZmU9dent7DXg8XiuOYwQ9LoPJkItEYp5CoWAdCTg8t7SsbIadrW36iBFm5apyV1RUfmptbZWjvLkDABQXl8yiL+Z8vsDyoM+h2wghDAMMOTrOveDm5hKIYRh0dnaaVFZWTQEMQ6PMzQuNjY3q6fOisLBo9ujR1tmqvsUVF5fODP35l3AMXrf1goVfnLCztc08ciT4t7nJUeeIZDIZR1Vfaetod2z13LzBxGRIHUIATCZDzqCdZukoL6+YOmbM75snherqmkl6enrN+vp6zXQ7QghLuHlr65eLFoYqz/PKyqrJVlaWuTj+7meejo7Oob6H/BIk4t+/LdPh6rYk6B+ODpFBwcdiPp08+Q6DgStGjTIvHDZsWNWbvBAS+kt4fn6hgxqLNaC8PgAAvHdhRAiBsmA6BwDv5T+UUxVrMH962TffG1UmwTAMvY/7I386VA1sVaB95/stZmdnlymTyZBjOE7oaGt30Dkcx5GCIBgYhqHCgsI5YWfDQ0JDfpqspvb2wkhpfR/o9R3sN70shmFAEAQDx3FisH6i1emtcSIUCg0xDAO5QsHS19MTAAAMDAxo9PX16evp6TVLpVLNy7FX9/b09Bjv8PZa/T6tqrg/qe0P+1B1PgwAEL3Mm1AIr6mpnVRYWDTbxWXxUaU4gBDCGpuaxowwMyslSfK9Gv/sHKBrpNrhQ/BHeZTjvrHTbYOOr5cv6yYYGBi84vF02v+qjj/TDh/iQ/FUHbq6uoZqamoK2Wy26E19EL1OCQm3vDq7uoYuWuj8s0JBsOrq6sZfuhS7/9ixoOksFkvlfw3vXRj/H/8+4q7f2NHS3GKBM3CFh/uGrcqdnZeX73gmLDwEAMHePd9/NXLkiNL/kNQPRmrqwxWlZWUzFAqF2ratW75jMpmKkpKSmcn3U9fq6+kJ7iYlb5g4cULqDm+vVWpqLNl/Wu9fwR9NzP8rSE/PcFUoCJaq29//FiTcvL2VIBRMlyWLf1LF9/b26R0/Hnq+uKR0loaGep+drW3Gl4sXHR9tbfVisJj/Ba3fH+3UesiIAAAAAElFTkSuQmCC"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Prochlorperazine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:210pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Progesterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">The oral capsules are contraindicated for use during pregnancy.</p><p class="s4" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events following maternal use in pregnancy (eg, hypospadias, congenital heart disease, cleft lip/palate) have been noted in post marketing data; however, a causal relationship has not been clearly established. Use of vaginal progesterone may be considered to decrease the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and prior spontaneous preterm singleton birth (therapy may begin at 16 to 24 weeks, regardless of cervical length). It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix &lt;20 mm before or at 24 weeks&#39; gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012). The vaginal gel and insert are indicated for use in ART.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Progesterone is present in breast milk.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">The manufacturer recommends that caution be used if progesterone is administered to a breastfeeding female.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Propofol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Propranolol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Propylthiouracil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo/Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Protamine Sulfate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo/Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pseudoephedrine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pyrazinamide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pyridostigmine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Pyridoxine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Quetiapine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rabeprazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rabies Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Raloxifene</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ramipril</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ramucirumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ranibizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ranitidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rasburicase</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Regorafenib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Remifentanil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Repaglinide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ribavirin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ribociclip</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and data from animal reproduction studies, ribociclib may be expected to cause fetal harm if used during pregnancy. Women of reproductive potential should have a pregnancy test prior to treatment and use effective contraception during treatment and for at least 3 weeks after the last ribociclib</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">dose.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if ribociclib is present in breast milk. Due to the potential for adverse events in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for at least 3 weeks after the last ribociclib dose.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rifampicin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rifaximin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rimexolone, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Risperidone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ritonavir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rituximab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rivaroxaban</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rivastigmine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rocuronium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Romiplostim</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Romsozumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Romosozumab is not indicated for use in females of</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">reproductive potential.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if romosozumab is present in breast milk.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rosuvastatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated 1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rotigotine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Information related to the use of rotigotine in pregnancy is limited (Dostal 2013).</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Available guidelines note there is insufficient evidence to recommend rotigotine for use in pregnant females with restless leg syndrome (Picchietti 2015) or Parkinson disease (Seier 2017)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 17pt;text-indent: 0pt;text-align: left;">It is not known if rotigotine is present in breast milk. Rotigotine decreases prolactin secretion and lactation may be inhibited.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Rubella Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ruxolitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Salbutamol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Salmetrol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Secukinumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Selegiline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:181pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Semaglutide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2020; Blumer 2013).</p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Agents other than semaglutide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2020).</p><p class="s4" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">In females of reproductive potential, semaglutide should be discontinued for ≥2 months prior to a planned pregnancy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: justify;">It is not known if semaglutide is present in breast milk. The oral formulation also contains salcaprozate sodium (SNAC); it is not known if SNAC is present in breast milk.</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, the decision to breastfeed during therapy with injectable semaglutide should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Senna</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sertraline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sevelamer</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sildenafil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Simethicone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Simvastatin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated 1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:27pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Siponimod</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It may cause fetal harm. Disease modifying therapies are</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">generally not initiated during pregnancy</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if siponimod is present in breast milk.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sitagliptin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sodium Acetate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Sodium requirements do not change during pregnancy</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">(IOM, 2004).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Sodium is found in breast milk. Sodium requirements do not change during lactation (IOM, 2004).</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 15pt;text-indent: 0pt;text-align: left;">Sodium Alginate + Potassium Bicarbonate (GAVISCON)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Most aluminum-containing antacids are considered low risk during pregnancy; however, use of antacids containing magnesium trisilicate should be avoided (Mahadevan</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">2006).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Most aluminum-containing antacids are considered low risk in nursing women (Mahadevan 2006).</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sodium Bicarbonate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:45pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">Sodium Glycerophosphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Phosphorus requirements are similar in pregnant and nonpregnant women</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Phosphorus is a normal constituent of human milk (IOM 1997)</p></td></tr><tr style="height:81pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sodium Phosphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Animal reproduction studies have not been conducted.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Phosphorus, sodium, and potassium are normal constituents of human milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">mother.</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 29pt;text-indent: 0pt;text-align: left;">Sodium Polystyrene Sulphonate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration. Use during pregnancy is not expected to result in significant exposure</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">to the fetus.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Sodium polystyrene sulfonate is not absorbed systemically. Breastfeeding is not expected to result in significant exposure to a breastfed child.</p></td></tr><tr style="height:75pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 36pt;text-indent: 0pt;text-align: left;">Sodium Potassium Phosphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted with this combination. See individual agents.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">It is not known if potassium phosphate and sodium phosphate are excreted in breast milk. The manufacturer recommends that caution be exercised when administering potassium phosphate/sodium phosphate to nursing women.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAgIAAAAICAYAAACLQZeDAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAAgAElEQVR4nM17d1hTWfPwuSEJLZBgaKH3jjQVAZWmCCLi2is2FlfX7uq+uuvq2isWFBG7iNhponTpHQEFpCQQehJKICGk3eT+/sDrxrxY3u/9fd/zzfPc58mZOWdmzpxzz5k7M4EaGho96+sbZorFYkUVVRUOLIbx2jradGenyblEInEAyMHoKI/4Ni9/tSZ5Uo9IJFZEEATT29tr4evnE0/R1W2X7y8PfD6f0Eqlun14X++NUVCQaGtpdQIAwAiHo6mvR2l1cXHOwuPxwu/x+U9BKBQqJyWn7uzo6LBXwChIPL08XnpMd0+R7TM0NKSbl1+wcoqbW7qRkeFHFN/V1W2d8PjJn/I8168LO6itrdXV0tLqlp6e+bNAKFAlEon9SxYvOkcmT+qbSI+xsTE1Gq3NJT09M5xMntQzd27AbX19PeqPzEEkEillZeesi49/fPhi5DkPHR3tDlk6nd5h/yDu4XESkcjasWPb5q/x6e8fMHiTnhHR2NjodfrUCf8fkV1QWLS0srJqnkQiwRoaGjYtXrTwvOw6icVifEVFVbBIJFL29fV+NBEPBEHA8+cv91nbWFdMdnTIR/F8Pl/1ekxsFAzDOAAAcHVxyZo92+8BSu/r6zPLzy9c4T/b74GWpmb3RLzFYjH+6dMX/4IlMI6orj4gEApVJBIJ1sXZKdvOzrb0R+b4I1BVVT335s07kStXLT/m4z3rMYfDIR84eCh7x/ZfN1tbW1V8a2xj40dPIpHI+tH1/hpUVFYF3blz72xQ4NyboaEhVybqs//3g28DAwNu+vn6TLgW/y9gbGxMTSQWK5GIxP7/LZ6Dg0MUkUikrKFBYigpKY1N1IfP56uOjIxo605wHvF4PHUej0fS1tbu/JqM4ZERLS6HO4lC0aVhsVgYxSMIArW30x2xWKxYT4/SKksDYPyM6R8YMNCjUGgYDEYqSxOLxXgmk2miq0tpw2IVvhjX3dNjKRKJlPUoelQlJcUxVBaPxyPK64bD4YSKior80dFRIgAAkqVhsVixkpISbyKagoICrKysPIrq0sdgmCkrKY9qaU38Pv3/DAiCQCxWv5FUKlXQ0tLqlLcnCqOjPKJAICBoapJ75GnDw8NaCIJgNDQ0mBONFQgEKl/bXz8KIrFYcWhwUI9M1uzG4bDi7/UfGeGQ+fwxdW1tbToGg0HkaJpjY2PqJBKRqayszJOlicVivFgsVlRRUeHK85RKpRgej0dSU1Mbmkjm+JkLIQrXrl3tysjI2lTf0DBrz+6dG01NTd4nJaXsjrlx67Kzs1O27IXW1Nwy7cDBP3PnBQXecHNzzTQxMW4wMTGu19DQ6Nu//2CBHkWXZmho0PytyeJwOJGOjk7Hw/iEIzwej7h+/do/zcxM3xsZGTa+eJH02+Mnz/7wnjXr8f+2M3D5ytWb9nZ2xV5eni8lEgku8uLlu8rKylxbW5syAMYPCDq9wzEy8vJ9L0+PRB0dHToA45dXZmb2JhdnpxwHB4dCKyurSk2yZk9BYdHyZUsXn2lpaZ2anZO7fl5QYKytjU1ZVlbOhoSEJ3/5+Hg/mmhhxuev3XEj9tYlU1OTD7NmzXz2o3NQUFCAtbW1Ox4+fHR04cIFlwgE1RFZOolE6v9Q3zALlkhw8k6OLKiqqnB6enqsCgqLly1Z/NP578lNe52+mT00RAmYM/uukaFh0/0HcSeKiksWBwYG3EZtRKO1uTx5+uygQCAguE+bmjYRn8TE5D1Pnz4/aGllUWVhbl6D4uPjE444OjoUmJmZ1ZkYGzc4OTm+RV/CoaEh3ZZW6tSoq9E3AgJm3yGRSBNeKpcuRd1WUFCAN25Yd8DGxrrc3t6uqLbuvb+mJrl3ogvh/xT09PRoiUnJe5ycJueamBjX4/F4vq2tTampqcl7+cNfFiQSCfbwkWOpra2tU328Zz3+b3TQ19ejPn/xcr+tjU2ZjY11+UR9bGyty6ytLKtwOJzov5HV0tI6JTr6xtXBwUG9srLy0DNnzieIxWJFKpXm+vz5y/26ujptmprkXvlxnZ2dtvv3H8xXU1NjW1paVP83OgAAgEQiUbh2LSYaQaQYAkGVffHilbsEAoFtYKDfIqvro4QnhzAYjFRHR6dd9sCsqKicl5iYsltFRZmrpaXVNdEhz+WOajx6lHDY0EC/eWBgwPDS5ahbmpqa3RSKbtvo6CgpJTVtO43W5kql0lxv37573s7WtlhDQ4OJIAhISHhyqLa2zn+ShgbzekzsFaK6+gCFQmkDAIDEpJSdRUUlS7W1tbpiYmKv4PF4vqGhYZNYLMYnJibvbm5pde/s7LK/d+/BKSKR2G9kZNg0ODio/+ehIxkfm5o8Kioq51dUVM5PTk7dQVQnDqqrq/Xv23+gqKW1dSpKS0l5tR2RIhgzM9Pa7Tt217RSqVNQWvqbjJ8HB4f0nZwm59XW1vmVlJQuMjI0aGIyWaZxcfFH3d2npn5r79LpHfZRUdE3EhKeHIIlEmxTc4t7fX3DrBuxty76+frEyztE/zeBz+cTzp67EE+h6NJgGMafPx8ZZ2ZuWjtp0iQG2qeyqjowNSVtm6qqCkdLS7NLUVFRAMD4OfU2L3917tu81SQSsZ88aVKv7D2DIAhUU1M750bs7YvlFZUhs2bOeAYAAPSODvvLl6/eysrOWX/37oNT3T091s7Oztlfc0B6e/vM799/eEIkFinp6ujSVVSUuRgMBpFIJApH/j6W+iDu0bHk5NSdAoFA1cHBvghBEHDnzv0zg4ODBopKSry7dx+ccXJyzFVUVBRwudxJGRlZm2AJjIclElx19bvAwcEhPUNDg2YYlmCfP3+5DwAANTW3uD9//nK/i4tzFvrOZ2XlrOvs7LIfGhrSv3f/4XEzU9M6IlF9EAAABgcHKS9eJP127nzkw1mzZjwFCIKAS5ejbmzbvqsKQRCAIAhgMJlGgUEhyJWoa9dRnFAoVFy1Oqzn3PnI+yhO9rl/P+5Y6MIlPCaTaTQRXf45+Mdf6ceOn3wui3v//sOswKAQpPpdzWwUx+Px1EpKSkMzM7PX5RcULhUKhUoIggA2m63NZLKMmEyW0SiPp87lcklMJstoeHhEU16WRCKBOjo6bGVxx4+fenbm7IU4+b4/LVrGqat774O2pVIphMqUmevRjIzMDQiCAAaDYSxLGxpiawcGhSDNzS1TvjX/devD2+7cuXcKbcMwrFBSWrYgIyNrQ07u29VjY2MEWRvkvs1bmZWVE1ZSWrYgMCgEYTCYn+U2NTVPzcjMWp+VlR126vTZR5EXL99CaR2dnTalpeUhxSWlC1kslgGKf/MmI3zFyrUMqVQK2tvp9g0NjZ4SiQQzka7t7XR72XZ+QeHS4PmhYvl+ly5FxcruGdkn7fWbiKqq6oAtW3fUpmdkbkTxHz7Uzwhbt5F++869U/UNjZ5SqfTfxgqFQsXAoBCknf6lHrLPqdPn4n+O2NrQSqW6oDj28LBWa+s/7fZ2ukNpaVlISUlpKLpPe3p6zWtqav1aWlrdEAQBTCbT6FPbVXZtSkvLFmRl56wtKSlbsGFjROvbvPwVn/YH6OnpMedyuaRvrXdiYvLOJ0+e/R40b4Hk3bsaf3m6WCzGtbW1O3K5XFJNbZ2vUChUkkgkUFVV9dyysorgysqqQD6fr/rP/tnUnpiYvKO6+t2cV2mvfykvr5gnazsWi2XAYvV/Xu/Ozi6bktKyBSUlpaG9vX2mP/KOIggC6HS6vUAgUEYQBLS0troGBoUg/f39+rI6f23sX4f/Tk1Le7P5R2Whz8DAIKW3t89MFpeUlLL9yN/HE9E2lUpzmh/yk6Cvj2GCIAhIfZW2Zd++A3l8Pl9Fnt+9+3HHjh47+UIsFuO+Jffq1ehr0dE3LqPt0tLykGXLV7NgGFZob6c7yL4fsbG3zkdFRUcjyPi5FRa2kS6VSiEEQUBzc8uUZctX9fP5fJXGxo/Tf/ppKQeV3dbe7rB4yXI2jzdG6O3tNRvl8dRRnjk5b1fv2vVbKYIgoK+PYYLaGUEQIBKJ8Ddv3TkrlUrBwMCAHjpvdH9ei465IpFIMFzuKJFO77BDaVKpFLoWHXNFJBLhEQQB+38/mFNYWLwYpYet20jv7Oyy/t6axMcnHNqydXutLK69ne7A4/HU/tP1/dGnpbXVdWiIrS2LuxYdExUXF38EbWdkZG1YtnxVv0gkwkulUnDr9t3Tly5H3ZA/y8RiGHv8xOmnD+Lij0x0xqDrWFZWPj8mJvai7N2UlvY6AoZhBQRBAKu/32DN2vVd+fkFyybiUVxSGrpr928lXO4oUZ6W8PjpgcLC4sXoPkGfzKzsdVt/3VEju9ePHjvxAkEQEHPjZuTLxKRdKK2zs8s6MChEOjg0pPPiZeLup8+e7/s8Ljl1O3r2U6k0p337D7xFafX1DV4Rm3+tl0gk0NgYXzUjI3NDTW2dL3qXYCbyaN5V18xVUFAQ29vbFaK4puaW6UNDbD0rS8uqicY4ONgXCIVClbKy8tAf9e54vDH1/v4Bg/7+foP6+oaZt+/cO+Ps7JRta2NdBgAA7e10x78OH02zsbUp9ff3jeugdzj88efhDD6fryqVItD9B3HHN//yawNvdJTU0dFpHx+fcFgsFivKy8FgMIiRkdFHWdwYf0w9eF5gzPd0hCAIwePxArQtEokUS8sqQn0+hVx1dHS+CM/z+WPq9vZ2hZaWFhPaaSIQi2HcjdhbF/UoujQ/P584enuH4569+0tGRjjkkREO+eTJM08NDQya/P19H/Sz+o1kx7569Xrrm/SMCB8f74QpU9zedNA7HVBaYVHxkrNnL8S7ublk6FEoreE/b2lhMJgm/8gVK6akvtrW0NA481p0zNWoqOgJ7WFiYtzwxRzH+Grz5gVd/9H5vX2bt4pEIjHd3Fwz5WlEIrH/l18idkgkEuzJk2eeHjp0JH14eFj7R3mjsHVLxA5NTXLP9u27q3//1x+5BYVFSwmqqsMWFuORh7y8/JXnzkfGubm5ZpA1Nbs3btrcOjQ0pKunR6F9+FDvHXvzdiQAAGhra3fW1zfMuvmpLZFIFC5EXronEomU/P1849TV1QYHBgYMARgPyWVkZIZvCv+F2tbW7vQ13djsYe2m5hb3ZcuWnPH384mLvXk7UiKRKKD0gYFB/bPnIuOOHj2RlJKati3h0eNDBYVFS0+dPvekvqFxhrv71LT37z/4HPzjry/sV1tbN7u9nT6Zz+cTTp85nxB9/UYUAACUV1QGh/+8pbm0tGwhAOP74O+jx5OmuLmmGxgaNIX//EtLb2+v+Y/Y1djYuEFRUZE/EQ2LxYq1tLQ64x4+OpKdnRt28dKVWxcuXLonEAhUvsd33/4DeXFx8X9PRBsYGDDs6emxksWx2cO6QqHwM18jI8OPMAwrdnV327a1tU++fj32io+vd3x6RmZ4UlLKzuHhYS0AAKiufhfw4kXib56e0xNTUl9tS0lN+5XP5xMmkisWw3juKHcS2jYw0G/mcDhag4NDeiYmxvWyX830jk4HOzvbYgAAKC0rDzU1M62DIAgBAABzc7MaLnd0UlNT8/TCouIlhoYGTVjseGjY2MioYWyMr9bc0uJOoVDaVFVUOChPGq3Nxc5+nKeurg5dU1Pzc0j78eOnfwQHB12HIAiQyeReXd3xiCUAACQmJu8OCpobi8FgpASC6oixsVEjSktJTfvVx3vmY/Qr0d192qvbd+6evX3n3pn09MzwFSuWHf9eFHciqK5+F2BiYlyvoqLCfVdTOzvqanR0eUVl8PETp59VVFQGSyQSbHl5xfyjx04klpSULuTz+YTrMTcu02g0ZwAAyMzKXr9xY8Q3U2TNTS3ubPYQRRbHYDBMBTL7wNjYqIHD4WryxsaIZeUVCzIyMsOdJjvmJSWl7Hr9Oj1CLBbjAQDg5cvEvVQqzdVAX6/l5cukvVnZOeukUukX95+jo0OBu/u0V/IRxHnzgmIVFBQkAACgpanZraurS9PW0abL68vljmpERl6+6+w0OTc39+3aFy8S9zIYDFMAxtNVnR2d9o8SHh8KW7epI+31m80IgkAAAJCfV7DC1NSkDuXj5OT4trS0PJTH46njcDihrJ5isVgJAABJJRLsq1dvtjo42H++o6e4uaTn5uatgWEJNiMzK9ze3q4IpdnZ2RazWCzjtrZ2Z2VlJV5AwJy7DuN0BAAAPgsYHR3VKCwqXvLq1etf2un0yZcunnf/Ir/4SWlUeXnA4XBCAACAoK+HmOSBz+er9fT2WvX09Fo1N7dMG8/9aTBGR0c1AADgWnTMNRdnp2wNEomFwWCka9asOtzb22vx8mXS3kmTNJh79+xaN8PL8/mZsxfia2vr/Hft2h4+UT5IHgoKCpe5ODtn2dvbFf+orijk5xeumDXT6yn+03xlgccbU3/85NnB3/buDoOgCc00IVRUVITQ6R2OTFa/8bua2gADA/0mKyvLChaLZRJz4+ZlE1OTDxYW5jUQBAFv75mfw8pdXd3W0ddvRG2OCN+Fx+GEJBKpX3ZjmJuZ1WxYH3ZgYGDQgEajuYrFYsWRkREtlI7FYkULQuZfDQ4OigkODopppVLdvqcri9Vv1NDYOGP9urV//MjcSkvLFkAYjNTTY3ryRHRDQ4Nmj+nuKT+Hb9wXe+Oa/ejoKCkxMWXXj/CWBXV19cGTJ44GREdfmaynR6FeuHDp3qbwX1rq6xtmAACAmZlZ7eaI8F1DbLYuvb19skQiwY+O8jQAAIBAIAzL8lKROZzfvMmIYDJZprNmzXwKQRCwt7cr1vpU14LD4URz5wbcwuPx38wl3n8Qd2LlymXHAAAgLGztn319fRbp6ZnhKF1Tk9wzbeqU1xAGkq5csez4mTMn/Wb7+8XNme13LzAw4ObHj00eHA5Xs7u720aWr4uLc/bixT9dWLJ40fl9v+0OS0t7s1UMwzj3aVPTiET1z/U95mZmNVu3bN7OZg/rUFupbgiCQBwOVxOlS6VSjPyh+KNw5crVmyrKylwiUb3f09Mjsbauzj87O3fd98YdPLB/+eLFi86hbRiGsSKxWFEkFiuKYRgHwxIc2oZhGOvv7xvX2dll9+Jl0p72drpjesa4/dTV1AZKS8sW6uvrt3h5Tk8MXRASNcrjkXbs3FvF442pv0nPiLC2tqqY7j4tZWHogstNH5s89u79vVjWEUNhw4awA2IxrBgTE3v50aPHh9LTM8NVVFRG5M+UjMysjRYW5tW+vt7xAAAg4AsIWKzC5xwwBoORYDAYiUAgUB0bGyMqYLGyNASroAALBcIvnKWa2jq//oEBw/Xrwg7I61VZWRWkpKw8OlENVlNTsztfICCYmpjUy9NotDZnFotlYmdnV4LinJ0m58yZM/uumpraYMLjp38UF5cu7ujstPv6Sv0Do6OjGjm5b9dkZmWvf/rsxb9QfGdHp/0UN9cMN1eXDBKR2F9aWh6qoKAAu7tPe2VsbFz/IC7+WE7u2zUzvLyem5ub1wIAgK+PT/yZMyd95GXAMPx53SUSCVYMw3iZtkJISPDVnJy3awsLi5a0tLROKSgoXIbD4QRKioq8zIysjVZWVpXTp7snh4aGXH7//oPPn4eOpAMAQFFxyRJXV+esGTO8ngcHB11PT88MvxB56d6PzFsWampq/a2sLKtsrK3/rR6oqKh4CQRByNzAgFshIcFXCQQCe9v23dUDA4P6ysrKvP37966JvnbF+fSp4/4pKWnbExLG685EYrGyuvp4yB6A8RQwgiAKw8Mj2suWLj7DYDDN0tMzwpNTUrc/fPjoCIlEYqipqQ0yGAxTNTW1z+NUCQQ2DMOKHM6IZm9vn4UagcBGaRAEATU1whCbzf7sWPF4Y59rSbAokkAgsGfO8Hr+NQPY2FiXkUgkRiuV6joRvZ1Od8Tj8fxp06a++lGjamqSe5ydJucCAICzs1PunDn+99as3dDN4XDIx48dmdfZ2WXn9ImOToZAILB5Y2NEAMZfquXLl546cPDPnK7ubhsEQSDUK/8avH2bt0pZWZm7ZMmi7+bG5QFBEJCekRl++K8/FsrTBgeHKG/epG/eHBG+W1X1y9z9V+GTrnw+X01FWZk7beqU1yhpzhz/e0KhUIXJYJhpaZInLOhhMpmmCIJgMJhxb1UeJFIJNi+/YKWnx/SkmTNnPIu8eOXul+IhBHVYIPBtuwEAQFtb++Ta2jr/Hdt/jfiRvKBUKsXcuXv/jLa2dkdWVs56AABgMPrMXr5M2tPP6jdcs2bVF1+EqqqqI4uXLDrf0tw69Xu85aG+vn6mg4NDoamJSf3OHdsi1qxeefjkqbPPTp46+/RR/H09qVSKycsrWOXh4Z7k6emRePFS1J0f4ctgMk0hCPqqcwtBEPhWfrXx40cPGJbgqFSaG5VKcwMAAC8vzxdxcfHHvL1nPZat88Dj8EJZB3KUx9NITU3b5u/nG2dnZ1tUUlr609fkUCgUGoIgmIkcdalUopCdnbtuxkyvZ15eni8vRF6+L0tfv+HndhiGcVFXIqeQyf+e7/8W9PUxzENDQy6jTrX7g7uGCPLdrQTki7QaP3706urqtgUAACaTaSIUCFUGhwb1AQBAV0enzc3NNTPmepQjlUpz5QsEBCaTZeIx3T3JysqysqysPFRPj0JFi5sXLVp4IT4+4Uj/QL8hny9QMzE2/qCqqsoBAICVq5Yfi4jY2jQ2NkaUL6AiEokDfxz8fRkAAIyN8Qm/7fu9aM2aVUfQ9UUQBEpMSt5FIBDYG9aHfXaEjY2N6nNycsPQ9uDQkJ5UKlUwNTX5wGAwzaqqqoMQBAEQBIGREQ5ZDMN4Y2PDz1G2gsKipd1d3Tb/+v23lfJ7icFgmD5//nLfiRNHA+RtODIyonnvftyJo3//NV+eNjo6SroRe+vikcN/LpBZK7PtO3ZXv3zxRF1RUZEfumB+1G/7/lVYkF+4fO3a1YcvXY6KHR4e1v19/2+r0MJCWSAQCGx/P9+HAABgY/1PbYq7+7SUvLyCVVIEweBwWKFEIvl8r4StXX2otaV1SlZmzsZz507NQvE4HFY8UaFiTU3tbFZ/vzEAAHxsavIYHh7WQd8bK0vLyqlTpqRHXYmc0t3dY4PBYCSdnV12K5YvPamkpDQmhmFFGxvrMrT+I3h+0PUDBw7lAgAADMN4CwvzahwOJ8LhcKL5wfOu33/w8Li8/G9BfX3DjL4+hkX4pg2/TUTn8/lqampqQ7qf6ssCAmbfjb5+I6qnp8dK1pnU19dr3btn5/rk5NQdAACgoqzMEQlFyihdIBCq4nA4gYYGiamiosL9desv2wAYP0/z8gpWLlu25DQejxcQCIRhCQzj0XGjXC4Zh8MJSCQSi6iu3g9LxouvZflqaWl9EcFG4ZtfARwud9KHD/WzAAAAj8cL9u/bs7asrGJBc3PLFwf1wOCg3qtXr3/dt2/PGrSSnUqlufT19Zl9i788CAQCVQgCiB6FQgMAAD8/n7i3b/NW88bG1AEYD9MK+AKCv59vHADjX8TZOblh169fdeju6rG5eu169NcOIaFQqJyYmLzL3NysZvp091QEQUBbW/tkLnc8+iALXzvGGhoaZ5qamryX9d4+4b0KC4uWrVq14qiqquoIDMNY9EtUFqg0mkvqq9dbxnVEgI21VTkAAJibm717V1M750Hcw6MCgUBVKBIpPXv+4veBwUF9U1OT90XFpYuZzPGQvuhT6gOGYZy+vn4LHo/jy/6jQSQWKfL5fDUAALh/P+4EQZUw7OExPVkoFKogCAJJpVIFoVCoLK/btwBBEJCXl7+CwWCaLVq08CIWi4V5PJ56K5Xq8u+d//mJwWCkN2Ov2544/ncg+ujqUtoWLVoYuWbNqr8RBAF0Ot0BDd/BMIztoHfaz58fFP2f6AcAALm5+avb2tsno20ymdw3dYrba7QK+/ade2dJJCJz6tQpb9DQsEgsVhQKhcoQBpLw+XzCp5wqpre310L86QWjUHRpra1Ut6bmlmmfbAHBsBgPf9L5O3aDHj9+dnDLlogd/n6+D9Hn161btkIYSPoo4fFfX5ruH+ONjfEJ589fvO/v5/PQ1NTkA5fLJQMwnppCv95lL/3Gxo9ePj7e8fgJigPv3Y87qU5U7/cc3wfKCIJA4k9zBwCAs2dO+syfPy96dJRH+nGLj4O+PqUlNvbWRTSd09bW5lRaWvZvDgsMw9i2tvbJ6PvZ18cwG+FwyCh9sqNjfvC8oJjgeUExXp6eL6dOnfIabaMpJQKBMOzs7JTLZDBMabQ2l717d62HIAjY2dkWf/z40ROdDyJFMGQyuVtHW5s+xc31TW1t3ezPNpMiGGNjo3pVVdVheR1RaGho9Dpy5OiruQFzbi8MDbk0vh5jahcuXLqnqKg0ZmBg0Nz4scnj/oO4YxwOhzx7tt997ihPg0qluQAAQGZG1sbAwICbOjo69Dlz/O/icHhBdfW7QAAAyM8vWOnr4/2IQqG0wTCMu3P3/il6e4ejs4tzdlNzi3tiUvKuhoZGLwDGK9ePnzj9fMOGdQfkHW8YlmBPnzmfsHrViqOyqUsAxs/J06fPPV68aOEF2YJlMnlSr4YGiYmmTxUVFfm2tjYl0z4V984NmHNXT0+vlcliGX9v3WX/VXXk72OptrbWZV6eHomKSkq88XcExgIAQGZm1qa1Yav/MjUzrT1z9kI8ug58vkC1q6vbWp7v1KlT3qDr7mBvXzhzptcztI0WnWpqavY4OU3OLSoqXkImk3tWrFh2AgAA7O1si2pqamejewyRIhg7O9siAACws7Utqq2tm43KQRApxt7etkhePgAAwDKOzHhfBMrNzVsNwxLcvHmBNyAIAh0dHfby42xtbUrYbLZuf/+AATpORUWFa2ho8FEgEKrweDx1tC+V1uYSEDD7LgAALAidf6WmtnY2GqUqK68ICQkJviq7djAM465Fx1x1dHAoWBgacgWCIBC6YP6VvPzCFWifusS4k0QAAAbHSURBVLoPvr6+3vEYDEYaGBhws7i4dBFq774+hpmOjjbdyMjwc9pIFhSWLFk6Mzc3bw2Hw9UyNjaq19AgsdB8VnFx6aLYm7cuzp075zYWixVTKLptXl6eL3Nz367p7euzbG5pmdZGa3d+//6D76aN63+3t7P9HII6ey7y4eDgkL6rq0uWrEA+n0+ob2icmZeXv1ooFKoIhULl5uYW96rq6sDklFc7/f384tauXXVYQUFB4urqksVmD+tmZGZtYrOHdetq6/xDQ0Ou2NralLe2Ut2uXrt+ff26tX9M0tBgEklE1rNnzw+MjHC0zM3NamWrglmsfsO/jx5Pqa6uCSwoKFyRnJy6MzEpeQ+NSnMNDAy4CUEQEIlESu9qamdXVVXNU1TEC/T19Vvkq/IfJTz9c/GihZHq6uqfvySysrLXX7lyLZZKo7mmpLzakZycuvP585e/29vbFRsbf5lb7+rqtr19595Z7iiXbG9vVzRntv99CIIQDQ0Nlq2tTWlScurOR48eH87NeRs2P3jedUsLixo3N9eMITZbN+7ho6MdHR32XC6X3NfbZ6ExSYNpa2tdNm3a1LSkpJRdZeXloQwm05TJYJlKpBIchUKhkcnknuSUlJ0MJssUwkBSFqvfmNHHMNfX12str6gI6evrM7eytKzEYDCSgsKi5Z2dnfa2Njal8lXg0dE3riYmpex+//69X3Jy6s7k5NSdiYnJe0IXhEShNqJSaS7FJaWLh9hsPSNDw4+y+U1ZyMsvWGltbVVhamryAUEQTOTFK3dfJibtGRgYMOByR8keHu7J2traXWh/Lpc7qar6XVBdXZ3/JA1yr46OVsdE/8bo6Oi0b22lTunq6ralUmmu5eUVISwWy+Rfv+9bqaSkNCaBJbjklNRdLFa/MR6PF/b1McxYrH4TBwe7QhMTk/qKysr56emZERwOR1NNXX2IPTREoVB0aR4e05PV1NTYt+/cPdfc3OI+MsLR6u3ps1RTUxvS19drff++3qeionK+to52p4mpyQc0ZcRmD2s/efLsYG9vr6Wpqcl7LS2tz18/DAbTtKm52aOu7r2fqiphWFlJcbSgsGgZnU6fbGBo0ESh6FKxWKy4u7vHNi3tzVYul6tBJBFZNFqbq0QiwdrZ2RbjcXhBQ0PjzM7OTjsqjeYKYSDphvVhByEIAh8/Nk0vKipeSlAjDFtaWlSpKCtzk5NTd/X1McwxGIyExWIZM5ksEzs72xIVFRVuayvVTUdHp8Pa2qpyojUDYLyOoarqXVBLS8s0bW3tDi0tzW4lJSWem5trOpXW5nbz5p0L6RlZ4epqaoNz5vjf6+3ts8zOyV2Hw+GElpbm1S0trVNPnzmfEBAw+x4ejxeePHXmKW+UR5ooPcceZutIYAleNlfL5XIn1b3/4FtZVRU0SUODERa25i/0AtTX16MaGxs3vEpN24YgAJOVnbM+ImLTbk1NzV4bG+syVVXV4dzcvLVisUgxJ+dt2K5d28PRCIEs9PX1mb15kxEhFAlVwsLWHnJ0dChEIzQVlVXBEhjGCwQCAqOPYc7oY5iTyeReBwf7QjweL/TxnpVQVf0usL2d7kQiEVnLli45DUEQwOPxQj9f74cf6htmtbfTnXA4nGD16pVHMRiMtLa2zp/NZlMwGAhBeSIAQN7eMx9DEAQqK6vm6elRqF6eHknyun6ob5ipRiCwZ82a8W//OvpQ3+CtoICB584N+CLqpaCgAHt7z0oor6gI6evts2Cz2bouLk7ZZmam7wEAgMPhaBLV1Qfs7f9JJQAAAJ3e4ZCfX7hiYHBI38jI8KMmmdyD5swBAGBwYFD/VdqbLRgMRioSiZSbmlvctbW0uoqKSxZzRjhafn6+8aamJnUJCU/+6mMwLCwsLKqrq6uDYmNvXQoODvpqnVY7nT5ZS1Ozm0QisVBcf3+/QU1N3Zx3NbVzJjs6FCxYMP8aGgV2cLAvEopEyuXlFQv4Y3y1d+/eBW7btmUrHo8XuLq6Zvb29Fp+/NjkOTg0pNfc0jrtl80/71JQ+Kfyv7e31yI/v3B5Z2enPZpGVVZW4cbE3Lycl5+/uqGhceab9IyIlNRX2/B4vEB+72ppaXa7ODtlJyYl74YAALm5b9csXbr4rImJSUNZWcWCM2fPJ3R2dNl/qvpvmjzZMR8AACgUSpsiXnGsoqIypKenxxKCAFi+bOlp1Mbv3tXMSU/PDJ86beqb4E+OyKf5FjQ3NU9nsVhGVFqb68DAgOGa1auO4PE4oY6OdqeKsgq3vr7Bu6Oj06GpuWl62No1f6mpqQ0DMP6PAiqV5sbhcDQhCEL+ByGAP7loQiqcAAAAAElFTkSuQmCC"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACEAAAAICAYAAAB3R5aRAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAACdElEQVQ4ja2SX0hTcRTHf7+76/4Y3m2phU5a6a5I4gptPhjptCIIair2nEGFGkkQFssCHwxTJobh8kkK5OYwinQVaFD0l3BuEup0xpog9LD0ujt327Xu+fU0kJF78gsHDpzP4XzhezAhBO2EAACvrKwUzfsXKhYXA+Wh0HKJ7eyZfpY1TY+Nu680N12+tpXnnrhuK9PS4g0N9Q56JwxEo1H9xUvNiwX5B2Ys5ZaXNdXVw7mGnO+79fqfz56/uB4KLZuTd+rrbL2/4/EMQgiiAQBjjAnGeNsjhBBECKEoigJCCJJlmaZp+m9iHggsWSRJShei0cxqayWn0+nCqUyHw+G8jo7O8bgUT7/QeN5Odff0clNTntPJ4ObmpsozPX0KIYSCwR+Hurp6XACAfb6Zky0trd+2xlhWVjrhGhnOslZVck3NV2dnZ+eOpYp5aOhxd4Ep31tXa7vvfDg4oBgddX3MyzMEFArFH0EQstRqtYgQQpGIkN12w/7ebC55yzDM6ti4u1WWZZplWc+Ia7S9psY6LIoiE4vFtLFYTCtJ0i6jcd+8cb9xrvPuvacMk7FaWMh6/P6FimAwZC4tPTyZYJVKZdw/7z/K83yOKIpa7HD0PSouPvjBYMhdUmvUG6zJ5E04djoHH3z6/KVepVKJWq02vL6+vgdjTBiG+SUIQtb28SHcfuvmOZOpwDcx+aaR41x3KArD/1irtYpDAIAAALndr5oGnIP9PM9nr62t7fV6fcfb2uzveJ7PlmWZAgAsyzKV3G9TGAAQIQQBAErFAgDCiewiESGzu8fB+XwzJzQazUZRUeHX2lpbX7nlyOtUT7YT+gcdi2A4ItRjlgAAAABJRU5ErkJgggAA"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sodium Stibogluconate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Use of sodium stibogluconate in pregnancy has been described; however, the risk of spontaneous abortion may be increased in comparison to use of other agents</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sodium stibogluconate is excreted in breast milk</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sofosbuvir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Solifenacin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:157pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Somatropin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Data with somatropin use during pregnancy in women with hypopituitarism is limited; however, adequate replacement prior to conception may improve fertility (Vila 2019). The Endocrine Society guidelines for hormonal replacement in hypopituitarism suggest discontinuation of somatropin during pregnancy (ES [Fleseriu 2016]).</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">It is not known if somatropin is present in breast milk. Endogenous growth hormone is involved in the establishment of lactogenesis and use of recombinant growth hormone has been evaluated as a galactogogue. Although use may be considered in some patients, somatropin is not currently used in most countries; nonpharmacologic measures should be used prior to the start of</p><p class="s4" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">medications (ABM [Brodribb 2018]). Adverse events have not been reported in breastfed infants following maternal use (limited data). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sorafenib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sotalol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Spironolactone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sucralfate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:147pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sugammadex</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 19pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in some animal reproduction studies. Limited information is available related to the use of sugammadex for the reversal of rocuronium-induced neuromuscular blockade after cesarean section (Pühringer 2010; Stourac 2013). The effects of hormonal contraception may be decreased following sugammadex administration. An additional nonhormonal contraceptive (eg, condom, spermicide) should be used for 7 days after a dose of sugammadex in women using oral or nonoral hormonal contraception.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">It is not known if sugammadex is excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAUYAAAAICAYAAACF8lZYAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAASe0lEQVRoge1Zd1RU17r/zpkZZigDQxdRFCkiaCyJsUQlKlyuBjUKJJrYNQoqilhyNbGAAgIaIbGhIBpAURGxICJYkKKI9N6kOUMvA0xhZs7Z7w89yXEcjMl9efet9d5vrbPWnO+3v+/77b73GUAIgaqHJEnw8w+MdXFd2uXqtrSzvb1jKEII7ty5656Xlz+XKldVVT0pKvrSAZIk4ebN21vy8gt+45pbWkaeP3/BnyRJSE5OWf047clXFMcXCEZFRl70I0kS6LFu3Li5jW77qw9BEHhFReVkeiySJH97qHzx8Qle/26uN/mwlNQHK9LS0t3q6xts/zti/h1PfHyCV8yl2B/b29tNpVIp58SJUycGa2+BQDDq4cPHy1JSH6wgCAL7u7XdSby7MSoq5kBra9twmUym9ssvp04Opq2lpWXEg4ePvrmfkrqSIAhceezKZDK1svKKKdfjE7wCg45G+fr6XZfL5UyqTErqgxWlpWXTPlRbb2+v7uHDAdcePUpbSmlqaGi0iYqOOaCqvEQi0djovrnIxXVp15q131XTcycmJm2Ii4vfMdg4irt+w/vFi9x/KNeprLx8ikgk4tLt7e3tpvv3+9ySSCSaquKRJAlNTU3Wra2tZlKplPN39V1W1tOFLq5Lu11cl3ZFRf3eJv39/dq+h/yut7W1DaNsPT1C/YjzFwKodiRJEk6fOXuc0ieTyVlbt3lnu7gu7frm21WvJBKJxv/E3KA/OAwCkiQZNTU1H8+f/8+ws2GnbA0M9AUAAPn5BQ7hEZHBCCEMIQQXL0b5ZWY+XQwAWEFh4ZwzZ86GkiSJI4QgOvrSwZwXufMBALKyni4+f/7iEYVCwUQIQXTUJZ/nOa+5N/nw4yE/n7/4a/Thjo6OYYPp+lCIxWJudvbzBX19fXqULSHhlpePr19CQEDQFZlMxk5MTNrEFwislH3fdBb2Z3NytbS6uVytrq7u7iH/rv6/CxKpVCs5OWUdhuHk02fZi9IzstxIEqkcBxwOpx9n4AomgyGXSqVaf7c2mUzOSb6fsg4BwnJe5M578PDRSoVCwVJVls3miBk4Q8FisQYkEgmXsiOE4Oq169+vXbex5t695O94Ojrti79cFOLt7bWGyWQqqHJhYeEhAwMDmh+qDcMwsqCwcE5Nbe1EDHs9NK5cjdtTV9cwTlV5obDXsLGxyXbvnu+/Cjl+dCo9d0dH57BLl6/sIwiCSfcRiUTa2713PVXncPrHj//oEZ17kp7x1eHDAfE+vn4JCKHf7AwGU15YVDwnK+vpl6p0IISw9PRMt5TUhyvT0tKXfWh9/yyqqmom83i81rAzJ+zc3FwC6fpqamon3bx1x5Oy1dXVjY+Li99VWVX9KQBAbm6e061bd7a2traZAwCIRP28+vr6cV5enutPngidwOFwxH+X7sGANzQ02jU3N4+iNzYAAIPBIKZOnXKzorxiqq6ubitl9/DY6MnnC6wfPnz8bXFxiX1efoHjtq2bN2AYhrZs3uTR3tZulpiY5N7Y2GT7+PGTbzZv8tiEYRh4em5yFwqFRrdvJ26pr68f9yQ94+stm903UYMsLi5+p1Qq1Zw+beqN06fP/qKshwK1olO/B4O6unq/paVFXlVV9acIIQwAwNl5/sntXp7r169fu1NNTW1gMN/k5JR17h5bSp49e+5MEASDzpEkiQkEzRZpaelfvdWQOI4+/njSvdTUh6v0dHVblDXT47S1tw+ndniKHxgYUFdejBFC8CQ9wzUgICh2z959Kb6H/ON7enoMlfVSGxHlQ5IkriovAICVpUWuvr6eQF9fr9nI0LBJIpFoMRg4qaodeDxemy5Pt7W0rHyGhoZG32DtRYHa9AYDQRCMqKiYg/sP+N7Zs3dfSlR0zEE6bzHKvIDH47UaGxk1GhsZNQwMDKgzGAyFqlg6OtrtBoYGr4qKimdramoK6dyzZ9kLBwakGpMmTbw/e7b9JSsry1xNTY3eP9IP8Lp/ZTIZWyaTcahxAwCgpaUlNDU1rTY3H1lM2YYPM61kMZlyVXGMjY0abMeMyaqprZ2kra3dSecWL174k1gs1hYIBBZ0e15egWNDQ+PY/PwCB7lcrkbZZTK52pUr1/acOXPSbqjJkNrSsvLPKE5Xl9c247Pp1wsLi2er0oHjOJo1a+ZVHR2djpmzZlxR7p+y8vJpCoWCqez3+uQmY6viVOHzz2de5vP51ggBxmazpZSdw2FL5s+fF1ZTU/sxZRs//qOHn9vPig0PP3+UJEk88sKvAYsWLQg1MxteDgDA4/HaJ0wYn1pdXfMJj6fToSrf+9YH5TH/IXh9ypdqVlZWTZZIJJr4yZOnTwQcCb5CTSY6rK0sXwzIZBp0m76+XvPaNau+j7zwa8CFi1F+CxZ8cdLGZvRzAAA9Pd3Wje7fbbv4a5RfeMT5ow5z51y0tbXJeu2n37xxw/rtMZdiD4RHRAY7Os6NHDPG5ikAQHNzi3l0zGWf1atW7l29esXe5zkv5j99lr1IVQXi4xN2xF65thcAoKSkdKaqMmKxmLtn777U/PxCBz//I9fq6urHAgCwWCx5V1e3yXbvnc+6u3uMVPk+fPT4m7t377mLxRLto8d+ivLesTurvf33E2xERGTwmbBzodOnT034PZ9E68aNm1579+5PLSktnZn9PMeZHjMxMcnd3z/wKvV+PS5+1/IVa/iZmU+XkCSJnQk7F7p23YaaU6fCTtI7vEcoNEpIuLU9PSPT1dx8ZNHz5zlfSKXvnnICA49eqq19OREAIDs7Z0F4RGQQQgjup6Su2bfPJ4le1tDQsLGzo9P0zStC6N3TIkIIq66u/tg/IPDqpcux+1NSHqyWy+UsGg9lZeXT6WNGKpWqe2zyLCooLJwLACCTydh9/f08etyi4hL7xLv3PIqLS+zNhg8vKykpe6v/DA0NGzs7O03ftAFCCDEA4J3NoqamdsKRwODY6OgYn9TUh6sHZDIOxWMYBsFBAZ8HBQXYR0REBh8P+TlcJpOxleuoCn19/bxDh/xvuHtsKVm5al19Tk7uPDo/dKhJdUtLqzn1zmQy5T1C4TsbFYXRNtbZAoHAUtnO5XJ7DAwMmkQi8VvtM2PG9OsrVy7/kSAJFs5gEJT97t0kdycnx/NcLa0ec3PzIgFfYE33s7K2etEvEumq0oAQghMnT59qFjRbbN68tTAxMcmDzsfHJ+wICf0lXHlTzszMWrJli1f+mrUbaiMiIgP5fL6VVCrVIAiCoWpRMjMzK9PT1W3u7u4yUeZGjjArEYvEOtQ7hmHg4bHBs76+YWxg0NGYnp4e41Url/9I97EZPTq7WdBsoRwLAEAqlWq8fFk3QRWXkvJgzQ8/7L+vqh0oDAwMcPLy8h0BXm/WjY1NNoGBRy+HhZ0LuX79xs7Va76rYwYEHHYgCILFYDDeOTWw2RzJGJvXCxsdzs7zT6c9SV/a2tpqHuB/yJHOOTrMvZCZkeVaXlE5LTLynDl1IgQAcHJyDM/IzHKprq755Ie9/3KjuHPh549ZWIzKmzFjehyO4+iLL+adOXcu4qepUz69heP4W70wb57TWZlMzgEAiIqKObRtm+d6ptKufSQw+DKbzRZP+nji/cKi4tlsNlvS2to2AuD19ZDNZoslErE2AICoX8SjOACAq1fi9uza5b28vLzis36RSEcsFmv/GhXju8N721oAgP5+ES8vL/8fp0+f/Xnr1s3uCCE4cMAn0cjYqMHpn47n8nLznbKfZS+0nzXzChXT0tIyLynp3kaCIBgdHZ3DlixZfIwkES4UCg3T0p4s6+3tNTgS4DfH19cvobikZJaxkXED5bt7l/fyc+GRwQkJt7atXr1yL4ZhiK4XAMDOzjYj4EhwrN9hHydT06FVx0N+jhhjY/PMZMiQlw2NjXb08iRJMqRSqSYAgK6ubouOtvY7O3JBQeGckNAT4c5fzDttZja81MfX72Zm1tMlY2xsnlFl/PwDr65Zs3LPuLFjn1C2UaNGFba3dZgBAFyLi9+dm5vn9P3und9S/FATk9oA/0Nzt3vvevo47ckyX58D8+naCIJgSiVSLYQQrqOj3aGtzW3HMOytcVlaWjYjMOhYjLPz/FPmI0cUFxeXzkp/kuE2btzvOgAA1Dnq/Yd8D/4zOPinaHcPz5KDB35cwGazJbR2wLu7u43p+fftP5jk5uoSuHPn9pXR0ZcPCgQCKzrP5XK7+Hy+tUKhYDGZTDlLjSXV5fHeuh3QweVyu6wsLfJUcUOMjer19fX51DtCCIu/kbC9vKxi+vp1a3f2CoUGBgYGrzAMg+LiEvvyisppt28nbu7vF+n6+/m+Nef09XQFI0aYlajKU1v7cmJfX5/ewoXOJ6ZNm3IzKPhYjJOTYwRf0GypzuGIVq1c8cOP+w7cu3z5yj4Hh7kXKT8rK6vcgwf3LahvaBgbEBB05W5S8gZ1dY5o3Nixabt37/hWOQ+GYaCrq9tqbm5epMzxeLxWfX09Pt3G5XK7Pdw3bD167PivP/7wL1fl6zKXy+3+6KNxj0AFXrzInVf7sm6ClpZWtzI3cuSIoqZX/NEAAP39Ih0NDfU+hBDW0tJqbmo6tAYAoLWtbaSPr1/C7l3eyy/HXvthxmfT4pct+/oQh8MRAQBkZz9fgL3v6lNaWvaZmdnwMi6X+46AhobGMW1tbSMnT/4kSZnr6OwcWlxUYj97tv1lZa6tvX14eVn5dHv7Wb8tHCUlpTMAAxhrZ5cBACAUCg2ys58vcHR0iKQvrAAAt28nbmpqejVm06aNnmFh547nvMidhwH2ViVIROJaWlrdYrFYB5EIV55co22ss3d4e62+Fnd9d3Jy6jqcxpMI4RgGb+JhgGEY6e/n62hoaMAHAOjq6hqSkZHlamdnm25hMapQJpNx7iXfX/fqFX80n88fbWJiUpOfX+CAY29fT5ct+/rQsOHDKoODjkUDADCYDHnI8aNTKyurppw8FXYCkSTe0dlpqq2t3anGYknpvhx19X65XMYhFITqaw0GoKOj0y7seX164fF4bd093cYYYIjH02nr6RG+dTp2cJhz8euv3Y5UV9dMqqysmuLsPP80nS8vr5iam5fvxH/Ft+7q7h6iy+O11tTWTqK3s6amprBf1M+j27S4Wt1Hg4/MZDAYBEmSuMcmzyKSIN+51mhqagj7+kW6uFK/AADYfz4zdvm33/g0NDTa5uUXOC7+cmEona+qqv4kJyd3Hp/PH93R2WlqYKD/qqqqerLyGKCAAGHq6ur9EolUkxpJOAMnAF4vxJSfGltNMmHC+AeZmU9dent7DXg8XiuOYwQ9LoPJkItEYp5CoWAdCTg8t7SsbIadrW36iBFm5apyV1RUfmptbZWjvLkDABQXl8yiL+Z8vsDyoM+h2wghDAMMOTrOveDm5hKIYRh0dnaaVFZWTQEMQ6PMzQuNjY3q6fOisLBo9ujR1tmqvsUVF5fODP35l3AMXrf1goVfnLCztc08ciT4t7nJUeeIZDIZR1Vfaetod2z13LzBxGRIHUIATCZDzqCdZukoL6+YOmbM75snherqmkl6enrN+vp6zXQ7QghLuHlr65eLFoYqz/PKyqrJVlaWuTj+7meejo7Oob6H/BIk4t+/LdPh6rYk6B+ODpFBwcdiPp08+Q6DgStGjTIvHDZsWNWbvBAS+kt4fn6hgxqLNaC8PgAAvHdhRAiBsmA6BwDv5T+UUxVrMH962TffG1UmwTAMvY/7I386VA1sVaB95/stZmdnlymTyZBjOE7oaGt30Dkcx5GCIBgYhqHCgsI5YWfDQ0JDfpqspvb2wkhpfR/o9R3sN70shmFAEAQDx3FisH6i1emtcSIUCg0xDAO5QsHS19MTAAAMDAxo9PX16evp6TVLpVLNy7FX9/b09Bjv8PZa/T6tqrg/qe0P+1B1PgwAEL3Mm1AIr6mpnVRYWDTbxWXxUaU4gBDCGpuaxowwMyslSfK9Gv/sHKBrpNrhQ/BHeZTjvrHTbYOOr5cv6yYYGBi84vF02v+qjj/TDh/iQ/FUHbq6uoZqamoK2Wy26E19EL1OCQm3vDq7uoYuWuj8s0JBsOrq6sZfuhS7/9ixoOksFkvlfw3vXRj/H/8+4q7f2NHS3GKBM3CFh/uGrcqdnZeX73gmLDwEAMHePd9/NXLkiNL/kNQPRmrqwxWlZWUzFAqF2ratW75jMpmKkpKSmcn3U9fq6+kJ7iYlb5g4cULqDm+vVWpqLNl/Wu9fwR9NzP8rSE/PcFUoCJaq29//FiTcvL2VIBRMlyWLf1LF9/b26R0/Hnq+uKR0loaGep+drW3Gl4sXHR9tbfVisJj/Ba3fH+3UesiIAAAAAElFTkSuQmCC"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulbactam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulfasalazine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulphonamides</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:157pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulpiride</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulpiride crosses the placenta.</p><p class="s4" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p><p class="s4" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Sulpiride has been shown to cause hyperprolactinemia which may interfere with reproductive function. Use is not recommended in females of childbearing potential who are not using effective contraception.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sulpiride is present in breast milk.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Due to prolactin-stimulating effects, off-label use as a potential galactogogue has been reported (Zuppa 2010). A review article notes the estimated exposure to a nursing infant to be 2% to 18% of the weight adjusted maternal dose (Fortinguerra 2009). Breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sumatriptan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sunitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Suxamethonium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tacrolimus</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tadalafil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Tadalafil likely crosses the placenta (Sakamoto 2016). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014). Less than 0.0005% is found in the semen</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">of healthy males.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if tadalafil is present in breast milk. The manufacturer recommends that caution be exercised when administering tadalafil to breastfeeding women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tamoxifen</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tamsulosin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tazobactam</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:71pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Teicoplanin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies. The manufacturer recommends avoiding use during pregnancy unless clearly necessary</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 9pt;text-indent: 0pt;text-align: left;">It is not known if teicoplanin is present in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Telmisartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Temozolomide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Temsirolimus</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tenofovir Disoproxil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Terbinafine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Teriflunomide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:55pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Teriparatide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies; consider discontinuing treatment once pregnancy is recognized.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 17pt;text-indent: 0pt;text-align: left;">It is not known if teriparatide is present in breast milk. Because of the potential for osteosarcoma observed in animal studies, breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Testosterone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:118pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tetanus Toxoid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Animal studies have not been conducted. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 2011). The ACIP recommends vaccination in previously unvaccinated women or in women with an incomplete vaccination series, whose child may be born in unhygienic conditions. Tetanus immune globulin and a tetanus toxoid-containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women. Vaccination using Td is preferred.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tetracosactide</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:239pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tetracycline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tetracycline crosses the placenta. Tetracyclines accumulate in developing teeth and long tubular bones.Permanent discoloration of teeth (yellow, gray, brown) can occur. The pharmacokinetics of tetracycline are not altered in pregnant patients with normal renal function. Hepatic toxicity during pregnancy, potentially associated with tetracycline use, has been reported. Pregnant women with renal disease may be more likely to develop hepatic failure with tetracycline use.</p><p class="s4" style="padding-top: 5pt;padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided. Many guidelines consider use of tetracycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant women if other agents are available and appropriate for use (CDC 2020). When systemic antibiotics are needed for acne or dermatologic conditions in pregnant women, other agents are preferred.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tetracycline is excreted into breast milk.</p><p class="s4" style="padding-top: 5pt;padding-left: 29pt;text-indent: -24pt;text-align: left;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of exposure to the infant and the benefits of treatment to the mother. The calcium in the maternal milk is expected to decrease the amount of tetracycline absorbed by the breastfeeding infant.</p><p class="s4" style="padding-top: 6pt;padding-left: 29pt;padding-right: 4pt;text-indent: -24pt;text-align: left;">As a class, tetracyclines have generally been avoided in nursing women due to theoretical concerns that they may permanently stain the teeth of the breastfeeding infant. Some sources note that breastfeeding can continue during tetracycline therapy, but recommend use of alternative medications when possible. Breastfeeding is not recommended when tetracycline is being used for maternal treatment of acne. In general, antibiotics that are present in breast milk may cause non dose-related modification of bowel flora. Monitor infants for GI disturbances.</p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tetrastarch</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have been observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 30pt;text-indent: 0pt;text-align: justify;">It is not known if tetrastarch is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetrastarch to nursing women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Theophylline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Thiamine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Thyrotropin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ticagrelor</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tigecycline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Timolol, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:23pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tiotropium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:50pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 49pt;text-indent: 0pt;text-align: left;">Tiotropium and Olodaterol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: justify;">Animal reproduction studies have not been conducted with this combination. Beta-agonists have the potential to affect uterine contractility if administered during labor.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if olodaterol or tiotropium are present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:33pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tinidazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Hold Breastfeeding (Single Dose) Limited Human Data— Potential Toxicity (Divided Dose)</p></td></tr><tr style="height:221pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tinzaparin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">Use is contraindicated in conditions involving increased risks of hemorrhage, including women with imminent abortion. Tinzaparin does not cross the human placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012). Low molecular weight heparin (LMWH) is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors. LMWH should be discontinued prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered (Bates 2012). When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Small amounts of LMWH have been detected in breast milk; however, because it has a low oral bioavailability, it is unlikely to cause adverse events in a breastfeeding infant. Use of LMWH may be continued in breastfeeding women</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tiotropium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tirofiban</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hold Breastfeeding</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tizanidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tobramycin, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tobramycin, systemic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tocilizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:31pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tofacitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk (Contraindicated if Combined with Methotrexate)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">No Human Data—Potential Toxicity (Contraindicated if Combined with Methotrexate)</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tolterodine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Topiramate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Topotecan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tramadol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tranexamic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trastuzumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Travoprost, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tretinoin, Topical</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Triamcinolone</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible (Inhaled)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:54pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 46pt;text-indent: 0pt;text-align: left;">Tribenoside and Lidocaine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 9pt;text-indent: 0pt;text-align: justify;">Animal reproduction studies were not conducted with this combination. Systemic absorption occurs. Avoid use during first 3 months of pregnancy and do not exceed the</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">recommended dose</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">According to the manufacturer, this combination may be used during breast-feeding. Do not exceed recommended dose. Also see lidocaine monograph</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trihexphenidyl</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:53pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trimetazidine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were not observed in animal reproduction studies. The manufacturer recommends avoiding use during pregnancy.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 32pt;text-indent: 0pt;text-align: left;">It is not known if trimetazidine is excreted into breast milk. Breast-feeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trimethoprim</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human and Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:55pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Triptorelin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to triptorelin may cause fetal harm.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends that a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tropicamide, Ophthalmic</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trospium</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:43pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Trypan Blue</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Adverse events were observed in animal reproduction studies.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 30pt;text-indent: 0pt;text-align: justify;">It is not known if trypan blue is excreted in breast milk. The manufacturer recommends that caution be exercised when administering trypan blue to nursing women.</p></td></tr><tr style="height:56pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Tuberculin Test</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Animal reproduction studies have not been conducted. Pregnancy is not a contraindication to testing.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if tuberculin purified protein derivative (PPD) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tuberculin tests to nursing women.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Typhoid Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:95pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 37pt;text-indent: 0pt;text-align: left;">Umeclidinium and Vilanterol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: justify;">Animal reproduction studies have not been conducted with this combination. Beta-agonists have the potential to affect uterine contractility if administered during labor.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">It is not known if sufficient quantities of umeclidinium or vilanterol are absorbed following inhalation to produce detectable amounts in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">benefits of treatment to the mother.</p></td></tr><tr style="height:77pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upadacitinib</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on data from animal reproduction studies, in utero exposure to upadacitinib may cause fetal harm.</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 4pt;text-indent: 0pt;line-height: 13pt;text-align: left;">It is not known if upadacitinib is present in breast milk.</p><p class="s3" style="padding-top: 3pt;padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 6 days following the last dose of upadacitinib.</p></td></tr><tr style="height:68pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Urofollitropin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multi-fetal gestations/births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 9pt;text-indent: 0pt;text-align: justify;">It is not known if urofollitropin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">treatment to the mother.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ursodiol</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Ustekinumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Valacyclovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Valarian</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—No Relevant Animal Data</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Valganciclovir</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Valproic acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Valsartan</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 2nd and 3rd Trimesters</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vancomycin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Varenicline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Varicella Zoster Vaccine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vasopressin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vedolizumab</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Animal Data Suggest Low Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Probably Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Venlafaxine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk in 3rd Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Potential Toxicity</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Verapamil</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr></table><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vigabatrin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:85pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vildagliptin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Adverse events were observed in some animal reproduction studies.</p><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 201 2018; ADA 2019; Kitzmiller 2008; Metzger 2007)</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if vildagliptin is present in breast milk; breastfeeding is not recommended by the manufacturer.</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vinblastine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest High Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vincristine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest High Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vinorelbine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vitamin C</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vitamin E</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Voriconazole</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:271pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Vortioxetine</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure.</p><p class="s4" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician (ACOG 2008). According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if vortioxetine is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAHsAAAAJCAYAAAASLVO1AAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAAJWElEQVRYhdVWeVCT1xY/SSCBBJKAkCBbQTaxEqlIBapgsep7KiqxUEU6r7ZoBbVa7aL0oSgulaq0Fe1rtbjgVhWVhyAgtbgUA2EXIkRCCCGQAAlJSMj+3fcHDY9h9PmcaafTM3NnvnvOd8492/3dAwgh+Kuscq5wiUfCCUM9Xxr+Z/vyRyylRk87V96y7o3NF3jZl6t3/972//QAX2aZzBabhg5ZmMWC4f5sX/7AGAkMdi76I4qNh78Q2RDw5uk+Lo0IEG4832iyEK3fWr2JgmH/lVssGGFEbyI/z6bFghE0OqMDQuiF5xtNFqL1P73RTDKaLbZWGUIINDqjw/izxxOGIZxWb6SYLRjhWXKERuU4gBc7AgBmC0bQ6o0UhBBMtGn1Ras3UcbHZXO1si35y8vV+6a94tKcvT4m1WjGiCcKGz4pqe5kpywO+fbdBa/+4Ey1l9+p61qcfblm78GU6I1Ngv7wr6/XpUezPCuy3pvz8YBKxzx8pWYXh9cX80lieObK6MALDvZEzaW7T9beeMBfvee9OdtKqjvjz5S1pLHnBl74IjliJ08kZ315qXpfq3Aw9EDK3E1LI/wKTGaMeOxm/eddUpXfP9dE7mQ6U/qsjgp6hwJPl7akXv6lbW1B5vL5rCmudeW1XXG5N+s/M5ox4uYVMw89bOmJ5bZJoxTDOpcTWxasud8sXtDdP+xT91QWQSUTVTf2xs+j2NlqAQAetUqi7zf3vOXNpAqlCq37mdKW1Kz353y8LMr/6sTE1rZLI04WN20pqRbG3zrAjiqp7mQ3CQbCOE965x7+cN6HCBDuwWPJfJFMPUXYp/Q/8/ni+JkBzBoAgMfCgdBiTifb140m6JAMBf1U2faPHatnZyTNn5YHACAZHPb6uqAufaY/s8aGgDOX1XYte1Ghrz/gr+qQDE2d7uva2CVV+Rf+2pFYlp3wOgDAufKW9SXVnfFJ86flCXqVAecreOtz0t58P5rldRcQQrDvfNX+4PdOyYZHDA4IIRjRm+wD3v1BkZVfdcAKAecrWt+/+DNvrXWfmlN+PmJjfrvJbCEghEAkVflMfvu46VRx0ybrPznXuOkNT2VhCCHAMAzYu29WpHx1+yervJ4vDWewc1ExR7DCyss88zC7Z0Dt9SwYKq3pjGOwc1Fjx6hNhBAk7iksjdiY367S6GkIITCYzLZhH54VJu0vKtIbTSSEEEjlmskMdi66WDHq/9V7bWuiNp1/ojOMyhFCkLS/qGjr8Z9PPg8Cv71e+zmDnYu6pEpfKy/5wK3C2Wn5/D65ZjJCCCwYhpu14Zxg3ZHSSwghaBfLp7JSTvd096u8e+XD7r3yYfePjlXkMdi5qLa9b7a4X+01I+W0ePwMolDrnF8E4yEf5EluPeqIt+7H5zxm68Xm8bqx2y7Xb//u7vdjML55xcxsDAH+ZHHzFgCARoFslp+7U/vJ4qatkoFhL73RbFfC6WQnzgs6a+2uT1e9vru7X+179V77uwAADR394awprvWHr3B3q7QGmkKtm9QtU/uG+jPqAABwOBykJ83+oogjeLtFODgDAIDzpHduqD+jJiu/6pDJbLHtkqr87Eg2Og8XR/GzOhqPw2ETeURbgsGRTFRTKSQVAADRhmCiO5AU7s4OEpKtjQEAwJVOlgIAWDDMBgCg8NeOxCnu9Kd2xFE5AMCF9KVxOWmx6553m+gOdkMAAN4MqtDKYzqRpY5kotrtNwTC43CI7kAa0upNjgAAHF5vNJlkoxVJ1X4CiTJIIFEGJcQE5RdkLo/1caMJ/lXUuK1PofV4LYDJtdqkUUhDz7/To5QUG5y37kjZlYWfXeGeLG76KC7SbwyNKnNWs1bHBp/OL29dd6GC94FKa6CP5Q8AgEohqbauDDvw3b8bt/crR5gXKp6kXN+zPJbpROk9cJGzP+/2440fLA45RsDjx5Lt60YTrHoz+PTRq9xdA8oRRmVT96KfMpYtQgDwTUFd+vHChk83rnjtq/FOhgW6VS8I8yk+dLl6L1+sCB5U6Rgnty96RzKo8T5b3rrhh1tNW1LjQo++KNjfgXBt3fJXx7+5AKOQ+v+83S9zjlytd53u69I4J8TzF+uKmOZ+H0MIrzOYKQCjc8bLGP04YdY+Tm5yQFyk37W82483hq4/21PKFS6zWDBC2jd38o8XNnyaMC8of81b0350crRTWPXGBrS1f5t+wpFMVMVn3KhMXRZ6xJ5kq/tncuSOggf8NbV8aeSbod5lEw/dlhCeJRsamfxOVlHZJ4nhe2gOJOX2hFl7T5U0f6QzmO393J34E3V2rJ6dcaeua+muMw+Pbk8M3+vNoHalLA459uWl6iw/dzrfekPNFsymqKrj7f4hrdvLJOI3euaQZC1j/JyAi939w77bTvxySm802wEAtIsV006XtqThcDhACEEZV7i0XawIHtN9ThP8r9aYFeRWpTea7ZZ+cf3XFuFAKIYh/JBG77T3XNVXRpOFGPua920cAHz2feV31iFLbzTbAwBgCI3VhsPrncvh9c6x7vflPzroxXDs2hwfdqjy6CqWl6ujqLVrcAavWx5ScJ+fHB3iWWFHtNFrdEYH9YiBpjOY7ZUaA52QmZkJAAA2BLzFyYGkcKGR+1dGB14CAAj0dOLdbxYvyEiO3Ml0okgnBkMlE9UKtc4lmuX5c8wM7woAANYU14ZbnM6V2etj0hzJxOGJOgw6WdYhUU7dEBea4zuZLgAACPVncisbuxcdXBe9yYoeDR2y8KT9t0rsSbYjb0z3uNcn13jc5nYulw2NuFPJRPUUdzqfJxpkVdSJllgQIvgwaYJJNPuBe03ihfeaxAsJBLzFm0EVku1sNbdrOuN5IjnLloA3B3o686Je9XjgzaB2nSlrST16jbvrx5LmzUqN3nnH6ogMki3BMKwzUhfvvFYtkqn92HMDL/HFiuAbD58mjRjNZFcaWTZ5koOkuXNg5t0G0d+HtQb6K0xqpyudLOO09sY8fNwTi8fhsKnezq0hvq6NC2f5FJXXCuMOX6nNPHKVu/tOnWjJlpVhB4O8Jj0J9HRu8/Nwajtb3pJ2/cHTNU2C/rDu/mFfbrs0iulE6XOl28s8XBx7lqQXVBU96kjYEBeag8PhIOdabQa3XRql1BicavnSSDweh21aMTPbi+Eo4onkrGM363cI+5QBRpPFTqHWu1Y2ihdRKUTVfwBjyNX/L2B9/QAAAABJRU5ErkJgggAA"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse;margin-left:7.24998pt" cellspacing="0"><tr style="height:16pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Warfarin</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Contraindicated—1st Trimester</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Compatible</p></td></tr><tr style="height:41pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Xylometazoline</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">According to the manufacturer, use during pregnancy is not recommended</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">It is not known if xylometazoline is excreted in breast milk.The manufacturer recommends that caution be exercised when</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">administering xylometazoline to nursing women.</p></td></tr><tr style="height:61pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Zavicefta (Ceftazidime/Avibactam)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse events have not been observed in animal reproduction studies conducted with ceftazidime; adverse events have been observed in some animal reproduction studies conducted with avibactam</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Ceftazidime is excreted in breast milk. It is not known if avibactam is excreted in breast milk.</p></td></tr><tr style="height:30pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Zinc Sulphate</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Zinc crosses the placenta and can be measured in the cord blood and placenta</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Zinc is found in breast milk; concentrations decrease over the first 6 months of lactation</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Zoledronic Acid</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Animal Data Suggest Moderate Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">No Human Data—Potential Toxicity</p></td></tr><tr style="height:15pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Zolpidem</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Human Data Suggest Risk</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Limited Human Data—Probably Compatible</p></td></tr><tr style="height:148pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;text-align: left;">Zoster Vaccine, Recombinant (Shingrex)</p></td><td style="width:279pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Based on the lack of data in pregnant women, the ACIP recommends that consideration be given to delaying vaccination with zoster vaccine (recombinant) during pregnancy</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">It is not known if components of this vaccine are present in breast milk. In general, administration of recombinant vaccines does not affect the safety of breastfeeding for the mother or the infant (ACIP [Kroger 2021]). However, based on the lack of data in lactating women, the ACIP recommends that consideration be given to delaying vaccination with zoster vaccine (recombinant) to breastfeeding mothers (CDC/ACIP [Dooling 2018]). According to the manufacturer, the decision to breastfeed following immunization should consider the risk of infant exposure, the</p><p class="s3" style="padding-left: 5pt;padding-right: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">benefits of breastfeeding to the infant, and benefits to the mother.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;line-height: 115%;text-align: left;">Adapted and extracted from Lexicomp and IMC Formulary – Jan 2022 Briggs Drugs in Pregnancy and Lactation</p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="123" height="9" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="514" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="33" height="8" src="data:image/png;base64,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"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"><span><table border="0" cellspacing="0" cellpadding="0"><tr><td><img width="326" height="8" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAUYAAAAICAYAAACF8lZYAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAASe0lEQVRoge1Zd1RU17r/zpkZZigDQxdRFCkiaCyJsUQlKlyuBjUKJJrYNQoqilhyNbGAAgIaIbGhIBpAURGxICJYkKKI9N6kOUMvA0xhZs7Z7w89yXEcjMl9efet9d5vrbPWnO+3v+/77b73GUAIgaqHJEnw8w+MdXFd2uXqtrSzvb1jKEII7ty5656Xlz+XKldVVT0pKvrSAZIk4ebN21vy8gt+45pbWkaeP3/BnyRJSE5OWf047clXFMcXCEZFRl70I0kS6LFu3Li5jW77qw9BEHhFReVkeiySJH97qHzx8Qle/26uN/mwlNQHK9LS0t3q6xts/zti/h1PfHyCV8yl2B/b29tNpVIp58SJUycGa2+BQDDq4cPHy1JSH6wgCAL7u7XdSby7MSoq5kBra9twmUym9ssvp04Opq2lpWXEg4ePvrmfkrqSIAhceezKZDK1svKKKdfjE7wCg45G+fr6XZfL5UyqTErqgxWlpWXTPlRbb2+v7uHDAdcePUpbSmlqaGi0iYqOOaCqvEQi0djovrnIxXVp15q131XTcycmJm2Ii4vfMdg4irt+w/vFi9x/KNeprLx8ikgk4tLt7e3tpvv3+9ySSCSaquKRJAlNTU3Wra2tZlKplPN39V1W1tOFLq5Lu11cl3ZFRf3eJv39/dq+h/yut7W1DaNsPT1C/YjzFwKodiRJEk6fOXuc0ieTyVlbt3lnu7gu7frm21WvJBKJxv/E3KA/OAwCkiQZNTU1H8+f/8+ws2GnbA0M9AUAAPn5BQ7hEZHBCCEMIQQXL0b5ZWY+XQwAWEFh4ZwzZ86GkiSJI4QgOvrSwZwXufMBALKyni4+f/7iEYVCwUQIQXTUJZ/nOa+5N/nw4yE/n7/4a/Thjo6OYYPp+lCIxWJudvbzBX19fXqULSHhlpePr19CQEDQFZlMxk5MTNrEFwislH3fdBb2Z3NytbS6uVytrq7u7iH/rv6/CxKpVCs5OWUdhuHk02fZi9IzstxIEqkcBxwOpx9n4AomgyGXSqVaf7c2mUzOSb6fsg4BwnJe5M578PDRSoVCwVJVls3miBk4Q8FisQYkEgmXsiOE4Oq169+vXbex5t695O94Ojrti79cFOLt7bWGyWQqqHJhYeEhAwMDmh+qDcMwsqCwcE5Nbe1EDHs9NK5cjdtTV9cwTlV5obDXsLGxyXbvnu+/Cjl+dCo9d0dH57BLl6/sIwiCSfcRiUTa2713PVXncPrHj//oEZ17kp7x1eHDAfE+vn4JCKHf7AwGU15YVDwnK+vpl6p0IISw9PRMt5TUhyvT0tKXfWh9/yyqqmom83i81rAzJ+zc3FwC6fpqamon3bx1x5Oy1dXVjY+Li99VWVX9KQBAbm6e061bd7a2traZAwCIRP28+vr6cV5enutPngidwOFwxH+X7sGANzQ02jU3N4+iNzYAAIPBIKZOnXKzorxiqq6ubitl9/DY6MnnC6wfPnz8bXFxiX1efoHjtq2bN2AYhrZs3uTR3tZulpiY5N7Y2GT7+PGTbzZv8tiEYRh4em5yFwqFRrdvJ26pr68f9yQ94+stm903UYMsLi5+p1Qq1Zw+beqN06fP/qKshwK1olO/B4O6unq/paVFXlVV9acIIQwAwNl5/sntXp7r169fu1NNTW1gMN/k5JR17h5bSp49e+5MEASDzpEkiQkEzRZpaelfvdWQOI4+/njSvdTUh6v0dHVblDXT47S1tw+ndniKHxgYUFdejBFC8CQ9wzUgICh2z959Kb6H/ON7enoMlfVSGxHlQ5IkriovAICVpUWuvr6eQF9fr9nI0LBJIpFoMRg4qaodeDxemy5Pt7W0rHyGhoZG32DtRYHa9AYDQRCMqKiYg/sP+N7Zs3dfSlR0zEE6bzHKvIDH47UaGxk1GhsZNQwMDKgzGAyFqlg6OtrtBoYGr4qKimdramoK6dyzZ9kLBwakGpMmTbw/e7b9JSsry1xNTY3eP9IP8Lp/ZTIZWyaTcahxAwCgpaUlNDU1rTY3H1lM2YYPM61kMZlyVXGMjY0abMeMyaqprZ2kra3dSecWL174k1gs1hYIBBZ0e15egWNDQ+PY/PwCB7lcrkbZZTK52pUr1/acOXPSbqjJkNrSsvLPKE5Xl9c247Pp1wsLi2er0oHjOJo1a+ZVHR2djpmzZlxR7p+y8vJpCoWCqez3+uQmY6viVOHzz2de5vP51ggBxmazpZSdw2FL5s+fF1ZTU/sxZRs//qOHn9vPig0PP3+UJEk88sKvAYsWLQg1MxteDgDA4/HaJ0wYn1pdXfMJj6fToSrf+9YH5TH/IXh9ypdqVlZWTZZIJJr4yZOnTwQcCb5CTSY6rK0sXwzIZBp0m76+XvPaNau+j7zwa8CFi1F+CxZ8cdLGZvRzAAA9Pd3Wje7fbbv4a5RfeMT5ow5z51y0tbXJeu2n37xxw/rtMZdiD4RHRAY7Os6NHDPG5ikAQHNzi3l0zGWf1atW7l29esXe5zkv5j99lr1IVQXi4xN2xF65thcAoKSkdKaqMmKxmLtn777U/PxCBz//I9fq6urHAgCwWCx5V1e3yXbvnc+6u3uMVPk+fPT4m7t377mLxRLto8d+ivLesTurvf33E2xERGTwmbBzodOnT034PZ9E68aNm1579+5PLSktnZn9PMeZHjMxMcnd3z/wKvV+PS5+1/IVa/iZmU+XkCSJnQk7F7p23YaaU6fCTtI7vEcoNEpIuLU9PSPT1dx8ZNHz5zlfSKXvnnICA49eqq19OREAIDs7Z0F4RGQQQgjup6Su2bfPJ4le1tDQsLGzo9P0zStC6N3TIkIIq66u/tg/IPDqpcux+1NSHqyWy+UsGg9lZeXT6WNGKpWqe2zyLCooLJwLACCTydh9/f08etyi4hL7xLv3PIqLS+zNhg8vKykpe6v/DA0NGzs7O03ftAFCCDEA4J3NoqamdsKRwODY6OgYn9TUh6sHZDIOxWMYBsFBAZ8HBQXYR0REBh8P+TlcJpOxleuoCn19/bxDh/xvuHtsKVm5al19Tk7uPDo/dKhJdUtLqzn1zmQy5T1C4TsbFYXRNtbZAoHAUtnO5XJ7DAwMmkQi8VvtM2PG9OsrVy7/kSAJFs5gEJT97t0kdycnx/NcLa0ec3PzIgFfYE33s7K2etEvEumq0oAQghMnT59qFjRbbN68tTAxMcmDzsfHJ+wICf0lXHlTzszMWrJli1f+mrUbaiMiIgP5fL6VVCrVIAiCoWpRMjMzK9PT1W3u7u4yUeZGjjArEYvEOtQ7hmHg4bHBs76+YWxg0NGYnp4e41Url/9I97EZPTq7WdBsoRwLAEAqlWq8fFk3QRWXkvJgzQ8/7L+vqh0oDAwMcPLy8h0BXm/WjY1NNoGBRy+HhZ0LuX79xs7Va76rYwYEHHYgCILFYDDeOTWw2RzJGJvXCxsdzs7zT6c9SV/a2tpqHuB/yJHOOTrMvZCZkeVaXlE5LTLynDl1IgQAcHJyDM/IzHKprq755Ie9/3KjuHPh549ZWIzKmzFjehyO4+iLL+adOXcu4qepUz69heP4W70wb57TWZlMzgEAiIqKObRtm+d6ptKufSQw+DKbzRZP+nji/cKi4tlsNlvS2to2AuD19ZDNZoslErE2AICoX8SjOACAq1fi9uza5b28vLzis36RSEcsFmv/GhXju8N721oAgP5+ES8vL/8fp0+f/Xnr1s3uCCE4cMAn0cjYqMHpn47n8nLznbKfZS+0nzXzChXT0tIyLynp3kaCIBgdHZ3DlixZfIwkES4UCg3T0p4s6+3tNTgS4DfH19cvobikZJaxkXED5bt7l/fyc+GRwQkJt7atXr1yL4ZhiK4XAMDOzjYj4EhwrN9hHydT06FVx0N+jhhjY/PMZMiQlw2NjXb08iRJMqRSqSYAgK6ubouOtvY7O3JBQeGckNAT4c5fzDttZja81MfX72Zm1tMlY2xsnlFl/PwDr65Zs3LPuLFjn1C2UaNGFba3dZgBAFyLi9+dm5vn9P3und9S/FATk9oA/0Nzt3vvevo47ckyX58D8+naCIJgSiVSLYQQrqOj3aGtzW3HMOytcVlaWjYjMOhYjLPz/FPmI0cUFxeXzkp/kuE2btzvOgAA1Dnq/Yd8D/4zOPinaHcPz5KDB35cwGazJbR2wLu7u43p+fftP5jk5uoSuHPn9pXR0ZcPCgQCKzrP5XK7+Hy+tUKhYDGZTDlLjSXV5fHeuh3QweVyu6wsLfJUcUOMjer19fX51DtCCIu/kbC9vKxi+vp1a3f2CoUGBgYGrzAMg+LiEvvyisppt28nbu7vF+n6+/m+Nef09XQFI0aYlajKU1v7cmJfX5/ewoXOJ6ZNm3IzKPhYjJOTYwRf0GypzuGIVq1c8cOP+w7cu3z5yj4Hh7kXKT8rK6vcgwf3LahvaBgbEBB05W5S8gZ1dY5o3Nixabt37/hWOQ+GYaCrq9tqbm5epMzxeLxWfX09Pt3G5XK7Pdw3bD167PivP/7wL1fl6zKXy+3+6KNxj0AFXrzInVf7sm6ClpZWtzI3cuSIoqZX/NEAAP39Ih0NDfU+hBDW0tJqbmo6tAYAoLWtbaSPr1/C7l3eyy/HXvthxmfT4pct+/oQh8MRAQBkZz9fgL3v6lNaWvaZmdnwMi6X+46AhobGMW1tbSMnT/4kSZnr6OwcWlxUYj97tv1lZa6tvX14eVn5dHv7Wb8tHCUlpTMAAxhrZ5cBACAUCg2ys58vcHR0iKQvrAAAt28nbmpqejVm06aNnmFh547nvMidhwH2ViVIROJaWlrdYrFYB5EIV55co22ss3d4e62+Fnd9d3Jy6jqcxpMI4RgGb+JhgGEY6e/n62hoaMAHAOjq6hqSkZHlamdnm25hMapQJpNx7iXfX/fqFX80n88fbWJiUpOfX+CAY29fT5ct+/rQsOHDKoODjkUDADCYDHnI8aNTKyurppw8FXYCkSTe0dlpqq2t3anGYknpvhx19X65XMYhFITqaw0GoKOj0y7seX164fF4bd093cYYYIjH02nr6RG+dTp2cJhz8euv3Y5UV9dMqqysmuLsPP80nS8vr5iam5fvxH/Ft+7q7h6iy+O11tTWTqK3s6amprBf1M+j27S4Wt1Hg4/MZDAYBEmSuMcmzyKSIN+51mhqagj7+kW6uFK/AADYfz4zdvm33/g0NDTa5uUXOC7+cmEona+qqv4kJyd3Hp/PH93R2WlqYKD/qqqqerLyGKCAAGHq6ur9EolUkxpJOAMnAF4vxJSfGltNMmHC+AeZmU9dent7DXg8XiuOYwQ9LoPJkItEYp5CoWAdCTg8t7SsbIadrW36iBFm5apyV1RUfmptbZWjvLkDABQXl8yiL+Z8vsDyoM+h2wghDAMMOTrOveDm5hKIYRh0dnaaVFZWTQEMQ6PMzQuNjY3q6fOisLBo9ujR1tmqvsUVF5fODP35l3AMXrf1goVfnLCztc08ciT4t7nJUeeIZDIZR1Vfaetod2z13LzBxGRIHUIATCZDzqCdZukoL6+YOmbM75snherqmkl6enrN+vp6zXQ7QghLuHlr65eLFoYqz/PKyqrJVlaWuTj+7meejo7Oob6H/BIk4t+/LdPh6rYk6B+ODpFBwcdiPp08+Q6DgStGjTIvHDZsWNWbvBAS+kt4fn6hgxqLNaC8PgAAvHdhRAiBsmA6BwDv5T+UUxVrMH962TffG1UmwTAMvY/7I386VA1sVaB95/stZmdnlymTyZBjOE7oaGt30Dkcx5GCIBgYhqHCgsI5YWfDQ0JDfpqspvb2wkhpfR/o9R3sN70shmFAEAQDx3FisH6i1emtcSIUCg0xDAO5QsHS19MTAAAMDAxo9PX16evp6TVLpVLNy7FX9/b09Bjv8PZa/T6tqrg/qe0P+1B1PgwAEL3Mm1AIr6mpnVRYWDTbxWXxUaU4gBDCGpuaxowwMyslSfK9Gv/sHKBrpNrhQ/BHeZTjvrHTbYOOr5cv6yYYGBi84vF02v+qjj/TDh/iQ/FUHbq6uoZqamoK2Wy26E19EL1OCQm3vDq7uoYuWuj8s0JBsOrq6sZfuhS7/9ixoOksFkvlfw3vXRj/H/8+4q7f2NHS3GKBM3CFh/uGrcqdnZeX73gmLDwEAMHePd9/NXLkiNL/kNQPRmrqwxWlZWUzFAqF2ratW75jMpmKkpKSmcn3U9fq6+kJ7iYlb5g4cULqDm+vVWpqLNl/Wu9fwR9NzP8rSE/PcFUoCJaq29//FiTcvL2VIBRMlyWLf1LF9/b26R0/Hnq+uKR0loaGep+drW3Gl4sXHR9tbfVisJj/Ba3fH+3UesiIAAAAAElFTkSuQmCC"/></td></tr></table></span></p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"/><p style="padding-left: 7pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Sanford online subscription 2022</p></body></html>
